## Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A

### prospective observational cohort study

KAMEN A TSVETANOV,<sup>1,2,\*</sup> LENNART R B SPINDLER,<sup>1,3</sup> EMMANUEL A STAMATAKIS,<sup>1,3,4</sup> VIRGINIA FJ NEWCOMBE,<sup>3,4</sup> VICTORIA C LUPSON,<sup>3,4</sup> DORIS A CHATFIELD,<sup>3</sup> ANNE E MANKTELOW,<sup>3</sup> JOANNE G OUTTRIM,<sup>3</sup> ANNE ELMER,<sup>5</sup> NATHALIE KINGSTON,<sup>6,7</sup> JOHN R BRADLEY,<sup>7,8</sup> EDWARD T BULLMORE,<sup>9,†</sup> JAMES B ROWE,<sup>1,10,†</sup> DAVID K MENON,<sup>3,4,5,†</sup> AND THE CAMBRIDGE NEUROCOVID GROUP,<sup>a</sup> THE NIHR COVID-19 BIORESOURCE,<sup>b</sup> THE CAMBRIDGE NIHR CLINICAL RESEARCH FACILITY,<sup>c</sup> AND THE CITIID-NIHR BIORESOURCE COVID-19 COLLABORATION<sup>d</sup>

<sup>a</sup> Cambridge NeuroCOVID Group: Anwar F, Allinson K, Bhatti J, Bullmore ET, Chatfield DA, Christmas D, Coles AJ, Coles JP, Correia M, Das T, Fletcher PC, Jubb AW, Lupson VC, Manktelow AE, Menon DK, Michell A, Needham EJ, Newcombe VFJ, Outtrim JG, Pointon L, Rodgers CT, Rowe JB, Rua C, Sithole N, Spindler LRB, Stamatakis EA, Taylor J, Valerio F, Widmer B, Williams GB.

<sup>b</sup>NIHR COVID-19 BioResource<sup>6</sup>: Kingston N, Graves B, Le Gresley E, Caputo D, Stark H, Townsend P, Stirrups KE, Chinnery PF, Bradley JR.

<sup>c</sup>NIHR Cambridge Clinical Research Facility: Saunders C, Elmer A

<sup>d</sup> CITIID-NIHR BioResource COVID-19 collaboration: Baker S, Bradley JR, Dougan G, Hess C, Goodfellow I, Gupta R, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Owehand WH, Saunders C, Smith KGC, Summers C, Thaventhiran JED, Toshner M, Weekes MP.

\* Corresponding author (kat35@cam.ac.uk, +44 1223 766 556)

*†* Equal contributions

<sup>1</sup> Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

<sup>2</sup> Department of Psychology, University of Cambridge, Cambridge, UK.

<sup>3</sup> Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.

<sup>4</sup> Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.

<sup>5</sup> Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

<sup>6</sup> NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK.

<sup>7</sup> Department of Haematology, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

<sup>8</sup> Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

<sup>9</sup> Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

<sup>10</sup> Medical Research Council Cognition and Brain Sciences Unit, Department of Psychiatry, Cambridge, UK.

COVID-19 severity and cerebrovascular burden

### Abstract:

Human coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has multiple neurological consequences, but its long-term effect on brain health is still uncertain. The cerebrovascular consequences of COVID-19 may also affect brain health. Here we assess cerebrovascular health in 45 hospitalised patients using the resting state fluctuation amplitudes (RSFA) from functional magnetic resonance imaging, in relation to disease severity and in contrast with 42 controls. Widespread changes in frontoparietal RSFA were related to the severity of the acute COVID-19 episode, as indexed by COVID-19 WHO Progression Scale, inflammatory and coagulatory biomarkers. This relationship was not explained by chronic cardiorespiratory dysfunction, age, or sex. Exploratory analysis suggests that the level of cerebrovascular dysfunction is associated with cognitive, mental, and physical health at follow-up. The principal findings were consistent across univariate and multivariate approaches. The results indicate chronic cerebrovascular impairment following severe acute COVID-19, with the potential for long-term consequences on cognitive function and mental wellbeing.

Keywords (up to five): cerebrovascular, microvascular, cardiorespiratory, neurology, COVID-19, SARS-CoV-2

#### 1. Introduction 1

2

3 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes human coronavirus 4 disease 2019 (COVID-19) with multi-system effects that include neurological, vascular and 5 neurovascular injury. Acute neurological sequelae are common, ranging from mild dizziness, 6 headaches and anosmia to severe encephalitis, stroke and delirium (Chen et al., 2020; Hensley et al., 7 2021; Paterson et al., 2020; Zubair et al., 2020). These sequelae may arise from systemic physiological 8 insults (e.g. hypoxia, hypotension, dysautonomia), coagulation dysfunction, large vessel occlusion, 9 arterial stiffness, impaired vasoreactivity, neurotropic infection, parenchymal haemorrhage, or 10 autoimmune responses against diverse antigens (Chen et al., 2020; Marcic et al., 2021; Mohkhedkar et al., 2021; Schnaubelt et al., 2021). Acute COVID-19 has also been associated with microvascular 11 injury from vasculitis or endothelialitis (Becker, 2020; McGonagle et al., 2021), with endotheliopathy 12 13 (Kakarla et al., 2021), vasogenic oedema and microthrombosis in the acute phase (Iba et al., 2020; Levi et al., 2020) and hypoperfusion in subacute phase (Hosp et al., 2021). While this acute 14 15 pathophysiology is detectable using neuroimaging (Hanafi et al., 2020; Lersy et al., 2021; Newcombe

# COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

et al., 2020), the persistence and effects of cerebrovascular dysfunction over the medium- and long-term remain unknown.

18

19 An important aspect of cerebrovascular function is the capacity of cerebral vessels to 20 constrict or dilate in response to physiological conditions such as alterations in carbon dioxide (CO2) 21 and oxygen tension. This cerebrovascular reactivity (Willie et al., 2014) regulates regional blood flow via pH-dependent modulation of vascular smooth muscle tone (Ainslie et al., 2005; Jensen et al., 22 1988; Lambertsen et al., 1961; Lassen, 1968), but is compromised by arterial stiffness, compromised 23 24 endothelial function (Brandes et al., 2005), or disorders including hypertension, traumatic brain injury 25 and dementia. Poor cerebrovascular reactivity may also increase the risk of neurodegeneration (Gao 26 et al., 2013).

27

28 We therefore assessed the impact of COVID-19 on chronic cerebrovascular reactivity after 29 hospitalisation. We use a well-established non-invasive imaging method, exploiting naturally 30 occurring fluctuations in arterial CO2 induced by variations in cardiac and respiratory cycles, which 31 moderate the blood oxygenation level-dependent (BOLD) signal underlying functional magnetic 32 resonance imaging (Birn et al., 2006; Glover et al., 2007). The BOLD signal variability at rest, known as 33 resting state fluctuation amplitudes (RSFA) is a safe, scalable and robust alternative to the gold 34 standard approaches (Kannurpatti and Biswal, 2008; Tsvetanov et al., 2020c, 2015). It is easier and 35 safer to apply in clinical cohorts than experimental hypercapnia, breath-holding and drug interventions (Keyeux et al., 1995; Rostrup et al., 1996, 1994; Wagerle and Mishra, 1988). RSFA is 36 37 sensitive to cerebrovascular and cardiovascular differences in ageing (Garrett et al., 2017; Tsvetanov et al., 2020b, 2015), small vessel disease (Makedonov et al., 2013), stroke (Nair et al., 2017; Raut et 38 39 al., 2016), Alzheimer's disease (Makedonov et al., 2016; Millar et al., 2020a), cognitive performance 40 (Liu et al., 2021; Millar et al., 2021, 2020b) and the presence of brain tumours (Agarwal et al., 2019, 41 2017).

We report on the chronic effect of COVID-19 on RSFA as a marker of cerebral microvascular function, in relation to acute severity. Exploratory analyses examine the relationship to normative regional variations in neurotransmitters/receptors, brain energy consumption and cell-type distributions. Acute disease severity was quantified by the COVID-19 WHO Progression Scale and blood biomarkers in patients hospitalised for COVID-19. We predicted that acute COVID-19 changes regional RSFA at follow up, in proportion to acute disease severity, over and above the effects of residual systemic cardiorespiratory impairment.

It is made available under a CC-BY-NC-ND COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

### 49 2. Methods

50

51

### 2.1. Participants

Patients were recruited through the NIHR COVID-19 BioResource, which received ethical 52 approval from East of England - Cambridge Central Research Ethics Committee (REC 17/EE/0025), and 53 54 provided written informed consent. Eligibility was based on admission to Addenbrookes Hospital with 55 COVID-19 between 10th March 2020 and 31st July 2020, aged 18 years or older, survived the acute 56 illness, and attended for a follow up visit, and no contradictions to MRI. 489 patients were potentially 57 eligible. Clinical data were obtained from inpatient electronic medical records, and from cardiorespiratory and neurological assessment at follow-up clinical and research visits at least 6 58 59 weeks following symptom onset. 45 patients consented to participate, with clinical, structural and 60 functional resting state functional magnetic resonance imaging (fMRI) data of appropriate quality (see below). Age and sex matched controls were scanned with the same sequences, with data pooled over 61 62 sequential cohorts to match demographics (Cambridgeshire Research Ethics Committee 97/290 and REC 17/EE/0025, and Norfolk EE/0395 and a protocol approved by the Human Biology Ethics 63 Committee of the Council of the School of Biological Sciences, University of Cambridge). The study 64 and their processing pipelines are summarised in SI Figure 1. 65 66

- 67
- 68

### 2.2. Inpatient data: COVID-19 severity

69 The WHO COVID-19 11-point Progression scale was used to provide a measure of disease severity with scores from 0 (non-infected) to 10 (dead) (see Figure 1 in Marshall et al., 2020). We also 70 71 used blood biomarkers previously associated with COVID-19 severity including the most extreme 72 values during hospitalisation on haematological (lowest platelets) (Wool and Miller, 2021), 73 inflammatory (C-reactive protein, CRP, serum ferritin) (Luan et al., 2021), immunological (inteleukin-6, 74 IL-6) (Group et al., 2021a; Ulhag and Soraya, 2020), hepatic (bilirubin) (Bangash et al., 2020) and 75 coagulatory (D-dimer, prothrombin time (PT) and activated partial thromboplastin time (APTT)) 76 (Asakura and Ogawa, 2020; Iba et al., 2020; Levi et al., 2020). Details of laboratory assay methods 77 used are provided in the Supplementary section. All blood-based measurements were log-78 transformed to transform the skewed data to approximately conform to normality. For consistency in 79 interpreting scores across blood samples, platelets values were inverted (iPlatelets) so that higher 80 scores represent lower count.

COVID-19 severity and cerebrovascular burden

82	2.3. Clinical visit: cardiorespiratory assessment
83	Cardiorespiratory measurements were collected during a clinical assessment at least 12
84	weeks after discharge from initial hospitalization with COVID-19. Systolic and diastolic blood pressure
85	(BPS and BPD) were measured in lying (or seated) and standing position using automated
86	sphygmomanometry using GE Carescape V100 Dinamap Vital Signs Monitor (GE Healthcare Systems,
87	Chicago, Illinois, USA). We calculated pulse pressure (BPS-BPD) and orthostatic hypotension (e.g. BPS
88	lying – BPS standing). Lying and standing pulse pressure values were log-transformed to transform the
89	skewed data to approximately conform to normality.
90	Lung function was assessed via CareFusion Micro 1 Handheld Spirometer (Vyairre Medical
91	GmbH.; Hoechenberg, Germany) to determine peak expiratory flow (PEF), forced expiratory volume in
92	1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio. Measurements were repeated in
93	triplicate, with one minute rest between measurements. Each variable was log-transformed to
94	approximately conform to normality. To balance the representativeness of each data type in the
95	imputations and data-reduction stages (see Supplementary Method), spirometry measures were
96	reduced to a single variable using principal components analyses (SI Figure 2).
97	Pulse oximetry, monitored via GE Carescape V100 Dinamap Vital Signs Monitor (GE
98	Healthcare Systems, Chicago, Illinois, USA), was used to determine the heart rate and arterial oxygen
99	saturation before and following a 6-minute walk test (Bois et al., 2012; Crapo et al., 2012; PL et al.,
100	2003).
101	
102	
103	2.4. Research visit: neurological assessment
104	2.4.1.Image acquisition and pre-processing
105	Imaging data were acquired using a 3T Siemens Prismafit System with a 32-/20-channel head-
106	coil at the Wolfson Brain Imaging Centre (WBIC; www.wbic.cam.ac.uk) during a research visit. A 3D-
107	structural MRI was acquired on each participant using T1-weighted sequence (3D Magenetisation-
108	Prepared Rapid Gradient-Echo, 3D MPRAGE) with the following parameters: repetition time (TR) = $2$
109	ms; echo time (TE) = 2.99 ms; inversion time (TI) = 880 ms; flip angle $\alpha$ = 9°; field of view (FOV) = 208 ×
110	256 × 256 mm3; resolution = 1 mm isotropic; accelerated factor (in-plane acceleration iPAT) = 2;
111	acquisition time, 5 min. T1 images were pre-processed using functions from SPM12 (Wellcome
112	Department of Imaging Neuroscience, London, UK) in Matlab 2020b (Mathworks,
113	https://uk.mathworks.com/). The T1 image was rigid-body coregistered to the MNI template, and
114	segmented to extract probabilistic maps of six tissue classes: gray matter (GM), white matter (WM),
115	CSF, bone, soft tissue, and residual noise.

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

116 RSFA was estimated from resting state Echo-Planar Imaging (EPI) of 477 volumes acquired with 64 slices for whole brain coverage (TR = 735ms; TE = 30ms; FOV = 210mm x 210mm; resolution 117 118 = 2.38 x 2.38 x 2.4mm) during 5 minutes and 51 seconds. Participants were instructed to lay still, to stay away and keep their eyes open, looking at a fixation cross. EPI data preprocessing included the 119 120 following steps: (1) temporal realignment of slices to (0,0,0) Montreal Neurological Institute (MNI) co-121 ordinates, (2) spatial realignment to adjust for linear head motion, (3) subjected to Artifact detection 122 tools (ART)-based identification of outlier scans for scrubbing (4) coregistration to the T1 anatomical image from above, (4) application of the normalization parameters from the T1 stream above to warp 123 124 the functional images into MNI space. We applied whole-brain independent component analysis of sing-subject time series denoising to minimise motion artefacts using a priori heristics using the ICA-125 126 based Automatic Removal of Motion Artifact toolbox (AROMA; Pruim et al., 2015a, 2015b) after 127 smoothing with an 6mm FWHM Gaussian kernel.

128 The initial six volumes were discarded to allow for T1 equilibration. We quantified participant motion using the root mean square volume-to-volume displacement as per Jenkinson et al (2002). A 129 general linear model (GLM) of the time-course of each voxel was used to further reduce the effects of 130 131 noise confounds (Geerligs et al., 2017), with linear trends and expansions of realignment parameters, 132 plus average signal in WM and CSF, CompCorr regressors, their derivative and quadratic regressors 133 (Satterthwaite et al., 2013). The WM and CSF signal was created by using the average across all voxels 134 with corresponding tissue probability larger than 0.7 in associated tissue probability maps available in 135 SPM12. A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete cosine transform set in the GLM, ensuring that nuisance regression and filtering were performed simultaneously 136 137 (Hallquist et al., 2013; Lindquist et al., 2019). Finally, we calculated subject specific maps of RSFA 138 based on the normalized standard deviation across time for processed resting state fMRI time series 139 data (Tsvetanov et al., 2020b). RSFA maps were smoothed by a 12 mm FWHM Gaussian kernel. 140 To facilitate integrative multivariate analysis (see below), the RSFA maps were parcellated by

141 a prior cortical template into 360 bilaterally symmetric regions (Glasser et al., 2016). Regional RSFA 142 values were estimated by averaging over all voxels in each parcel.

- 143
- 144

2.4.2. Quality of life, cognition, and mental health

Quality of life, cognition and mental health were assessed using a set of questionnaires: 145

146 Generalised Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Patient Health

147 Questionnaire-15 (PHQ-15), Posttraumatic Stress Disorder Checklist-5 (PCL-5) and subscores from the

148 Short Form-36 (SF-36). SF36 subscores were defined as physical functioning (SF36-PF), role limitation

COVID-19 severity and cerebrovascular burden

149	physical (SF36-RLP), role limitation emotional (SF36-RLE), energy dimension (SF36-ED), emotional
150	wellbeing (SF36-EW), social functioning (SF36-SF), pain (SF36-P) and general health (SF36-GH).
151	
152	Cognitive function and functional independence were evaluated using Montreal Cognitive
153	Assessment (MoCA, Nasreddine et al., 2005), inverted Modified Ranking Scale (mRS, Eriksson et al.,
154	2007), and Barthel Index (BI, Mahoney and Barthel, 1965). For consistency in interpreting scores
155	across questionnaires, scores for mental health questionnaires were inverted (iGAD-7, iPHQ-9, iPHQ-
156	15 and iPCL-5) so that lower values represent greater mental health problems.
157	2.5. Analytical approach
158	Statistical analysis used Matlab 2020b calling the packages as described below. We
159	performed a descriptive analysis of all the characteristics from inpatient, clinical and cognitive data
160	before integrating it with neuroimaging data as described below.
161	
162	2.5.1.Group differences in cerebral microvascular health
163	We performed component-based analysis, Source-Based Cerebrovasculometry
164	(Supplementary Material) to determine spatially non-overlapping RSFA maps without using group
165	information. Subject scores for each component was predicted by group identity (Patient vs Control),
166	age, and sex in a subsequence robust multiple linear regression. The model's formula was specified by
167	Wilkinson's notation, 'rsfa $\sim$ group*age + sex' and fitted for each component separately.
168	
169	2.5.2.COVID-19 severity predicting RSFA
170	The predictive specificity of COVID-19 severity on RSFA abnormality was tested using a
171	multivariate approach. We adopted a two-level procedure (Passamonti et al., 2019a; Tsvetanov et al.,
172	2020a, 2018, 2016). In the first-level analysis, the relationships between COVID-19 Severity and RSFA
173	data were identified using partial least squares (Krishnan et al., 2011). Partial least squares described
174	the linear relationship between the two multivariate data sets, namely RSFA maps and COVID-19
175	Severity data by providing pairs of latent variables (RSFA-LV) and (COVID-19 Severity-LV) as linear
176	combinations of the original variables that were optimized to maximize their covariance. Data set $1$
177	consisted of parcellated RSFA maps across all patients (45 patients x 360 nodes array, RSFA dataset).
178	Data set 2 included the COVID-19 WHO Progression scale and inpatient blood data (45 subjects x 9
179	measures array, COVID-19 Severity datasets). All variables were z-scored (mean of 0 and standard
180	deviation of 1) before entering to a permutation-based PLS analysis with 10.000 permutations to
181	determine the significance of the latent variables.

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

Next, we tested whether the identified relationship between COVID-19 Severity-LV and RSFA-182 LV could be explained by other variables of interest and variables of no interest. To this end, we 183 184 performed a second-level analysis using robust multiple linear regression and commonality analysis (Kraha et al., 2012; Nimon et al., 2008a). Commonality analysis partitions the variance explained by all 185 186 predictors in MLR into variance unique to each predictor and variance shared between each 187 combination of predictors. Therefore, unique effects indicate the (orthogonal) variance explained by one predictor over and above that explained by other predictors in the model, while common effects 188 indicate the variance shared between correlated predictors. Notably, the sum of variances, also 189 known as commonality coefficients, equals the total R2 for the regression model. We adapted a 190 commonality analysis algorithm (Nimon et al., 2008b) implemented in Matlab (Wu et al., 2021). This 191 192 model aimed to test whether the relationship between COVID-19 Severity and RSFA can be explained partly or fully by systemic cardiorespiratory dysfunction or other covariates of no interest. Predictor 193 194 variables included subject COVID-19 Severity scores from the first level PLS and systemic cardiorespiratory dysfunction (CRDPC1 and CRDPC2). The dependent variable was subjects' RSFA 195 scores from the first level PLS. Covariates of no interest included age and sex. The model can 196 197 therefore identify unique variance explained by each of the predictors i.e. whether COVID-19 Severity LV predicts RSFA-LV over and above other predictors. Common effects of interest were the 198 199 cardiorespiratory-related effects, defined by the common variance between COVID-19 Severity and 200 CRDPCA1-2. Significant effects of interest were identified with nonparametric testing using 10.000 permutations using commonality analysis implementation in Matlab (Wu et al., 2021). 201 202 203

### 2.5.3. Exploratory analysis

204 In an exploratory analysis, the level of RSFA abnormalities was related to component 205 measures of physical, cognitive, and mental functioning (PCM) using robust regression. The PCM 206 components, defined by principal component analysis (SI Methods), we defined as dependent 207 variables in separate models. RSFA, age and sex were entered as predictors. The model's formula was specified by Wilkinson's notation, 'PCM ~ RSFA + age + sex' and fitted for each PCM component 208 209 separately.

We further assessed the spatial overlap between COVID-19-related cerebrovascular burden 210 maps and a range of brain metabolic, neurotransmitter, protein expression and cell-type parameters, 211 212 including i) existing receptor/metabolic templates and ii) gene transcription profiling maps. Templates of interest included metabolic rates of glucose, oxygen, and aerobic glycolysis (Vaishnavi et al., 2010) 213 214 and receptor and transmitter maps across nine different neurotransmitter systems (Hansen et al., 2021b), all measured by positron emission tomography (PET). Gene expression maps (Hawrylycz et 215

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

216 al., 2012) were based on key proteins implicated in SARS-Cov-2 cellular attachment (angiotensin converting enzyme-2, ACE2; neuropilin-1, NRP1; neuropilin-2, NRP2), processing (cathepsin-B, CTSB; 217 218 cathepsin-L, CTSL) and viral defence (interferon type 2 receptors, IFNAR2; lymphocyte antigen 6-219 family member E, LY6E) (ladecola et al., 2020; Yang et al., 2021). Spatial correlations were evaluated 220 using spin-based permutations preserving spatial autocorrelation (spin-permutation test) (Alexander-221 Bloch et al., 2018; Fulcher et al., 2021). Spatial covariance between the cerebrovascular burden map and gene expression across 222 9394 genes expressed in the human brain (Hawrylycz et al., 2012) was based on regularized-PLS 223 association (Blankertz et al., 2011; Ledoit and Wolf, 2004) using spin-premutation-based 10-fold 224 225 cross-validations (Tsvetanov et al., 2020a). The latent variable represented a spatial pattern of gene 226 expression that highly covaries with the cerebrovascular burden pattern associated with COVID-19 227 severity. Full details about the processed transcriptomic data are available elsewhere (Arnatkevičiūtė 228 et al., 2019). Genes highly expressing this pattern (i.e. high loadings) were tested against a molecular atlas of human brain vasculature of 17 control and Alzheimer's disease patients (Yang et al., 2021) 229 using cell-type decomposition approach (Hansen et al., 2021a). This enabled us to test whether the 230 231 cerebrovascular burden-relevant genes are preferentially expressing in specific cell types i.e. testing for cell-specific aggregate gene sets in eleven major canonical cortical cell classes: astrocytes (Astro); 232 233 brain endothelial cells (BEC); ependymal (Epend); macrophage/microglia (MacMic); meningeal 234 fibroblast (MFibro); neuron (Neuro); oligodendrocyte precursors (Opc); oligodendrocytes (Oligo); 235 pericytes (Peri); perivascular fibroblast (PFibro); smooth muscle cells (SMC). To this end, we calculated the ratio of genes in each set preferentially expressed in each cell type (e.g. ratio for pericytes is 236 237 calculated from the number of genes preferentially expressed in pericytes divided by the total 238 number of genes). Gene sets were thresholded to include the top n% of genes with greatest loadings, 239 where *n* varied from 5% to no threshold. Statistical significance was determined using a null distribution of ratios based on 10.000 sets of random genes (Hansen et al., 2021a). 240 241 242

2.6. Data availability and code

243

Code and composite data to reproduce manuscript figures, statistical analyses are available at 244 https://github.com/kamentsvetanov/covid19 cerebrovascularburden. Resting-state fMRI data was 245 246 pre-processed using SPM12 (http://www.fil.ion.ucl.ac.uk/spm; Friston et al., 2007) and postprocessed using a GLM-like approach (Geerligs et al., 2017) available at https://github.com/MRC-247 248 CBU/riksneurotools/blob/master/GLM/. MATLAB-based commonality analysis for neuroimaging is

249 available at https://github.com/kamentsvetanov/CommonalityAnalysis/. Visualisation of

It is made available under a CC-BY-NC-ND 4.0 COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

- 250 neuroimaging results was in MRIcroGL (https://github.com/rordenlab/MRIcroGL; Rorden and Brett,
- 251 2000) and BrainSpace (Vos de Wael et al., 2020). Neurotransmitter receptor and transporter maps
- 252 were available at <u>https://github.com/netneurolab/hansen\_receptors</u>. Spin permutations (Váša et al.,
- 253 2018) used code available at https://github.com/frantisekvasa/rotate\_parcellation. Fully-pre-
- 254 processed transcriptomic data was available at
- 255 https://figshare.com/articles/dataset/AHBAdata/6852911 and
- 256 https://github.com/BMHLab/AHBAprocessing. The molecular atlas of the human brain vasculature
- was available at <a href="https://www.biorxiv.org/content/10.1101/2021.04.26.441262v1">https://www.biorxiv.org/content/10.1101/2021.04.26.441262v1</a>. Cell-type
- 258 decomposition analysis related code was available at
- 259 https://github.com/netneurolab/hansen\_genescognition.

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

#### 3. Results 261

#### 262 3.1. Participants

Characteristics of the 45 patients hospitalized with COVID-19 are detailed in Table 1. At

- hospitalisation, 30% of the patients required a mechanical ventilation (n=13) for an average of 20 264
- days; 22% of patients required vasopressors (n=10), and 9% renal replacement therapy with 265
- continuous veno-venous haemodiafiltration (n=4). The average number of days from initial symptoms 266
- 267 to clinical and research visit was 169±35 and 180±58, respectively. Data missingness is detailed in
- 268 Supplementary Results.
- 269

263

270

Table 1. Characteristics of 45 patients hospitalised with COVID-19. n - indicates number of patients and the 271 percentage of patients from the patient cohort (%), SD – standard deviation, IQR – interquartile range, kg – weight in

272 kilograms, m – height in meters.

Variable	n (%)	Mean(SD)/Median(IQR)*
Age (years)	45 (100)	52 (14)
Education (years)	45 (100)	16 (4)
Female	26 (58)	-
Right-handed	40 (89)	-
Inpatient data		
Vasopressors	10 (22)	-
Dialysis	4 (9)	-
BMI (kg/m2)	36 (80)	29 (4)
Mechanical Ventilation (days)	13 (29)	20 (15)
CRP	42 (93)	149 (147)
D Dimer	37 (82)	1125 (2071)
Ferritin	32 (71)	1225 (1700)
IL-6	28 (62)	39 (80)
РТ	32 (71)	26 (54)
APTT	33 (73)	42 (36)
Bilirubin	43 (96)	14 (8)
Platelets	44 (98)	230 (102)
Clinical Visit		
HR (bpm)	38 (84)	76 (14)
RR (cpm)	38 (84)	16 (2)
SBP lying (mmHg)	38 (84)	134 (23)
SBP standing (mmHg)	33 (73)	130 (20)
DBP lying (mmHg)	38 (84)	74 (12)
DBP standing (mmHg)	33 (73)	79 (11)
Research Visit	. ,	
GAD-7 (0-21)	44 (98)	4 (8)*
PHQ-9 (0-27)	44 (98)	7 (9)*
PHHQ-15 (0-30)	39 (87)	9 (8)*
PCL-5 (0-80)	44 (98)	16 (22)*
MoCA	39 (87)	28 (3)*
mRS	39 (87)	1 (1)*
BI	37 (82)	20 (0)*
Initial symptoms to Admission (days)	40 (89)	14 (14)
Hospitalisation Duration (days)	40 (89)	19 (31)
Intial symptoms to Clinic visit (days)	39 (87)	169 (35)
Initial symptoms to Research visit (days)	45 (100)	180 (58)

medRxiv preprint doi: https://doi.org/10.1101/2022.02.01.22270235; this version posted February 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity


perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

### 275 3.2. Group differences in Cerebrovascular components

- Using source-based cerebrovasculometry (Passamonti et al., 2019b; Tsvetanov et al., 2020b, 276 277 2015; Xu et al., 2009), we assessed the group differences in RSFA-based cerebrovascular components between controls and patients in small set of spatially independent components (n=8). Each 278 279 participant had one value per component, subject score, indicating the degree to which a participant 280 expresses the spatial map of the corresponding component. One component showed significant 281 difference between the patient and control group in terms of their subject scores (RSFA<sub>IC4</sub>, t = 3.12, p 282 = 0.003, Figure 1), while controlling for age and sex in a robust linear regression. The spatial extent of 283 this component, RSFA<sub>IC4</sub>, included voxels with high values in temporo-parietal regions, indicating that individuals with higher loading values, in this case the patient group, had lower RSFA values in these 284 285 regions, relative to the control group (Figure 1). The other components did not differentiate patients from controls (SI Analyses). 286 287 The spatial pattern of IC4 was consistent with the univariate approach (r=0.46, p<0.001, SI
- Figure 5). In addition, the univariate approach revealed that the spatial pattern in RSFA associated with age was highly consistent with the one reported on large-scale population-based cohorts, r=0.42, p<0.001 (Tsvetanov et al., 2020b, 2015). This suggests that RSFA can detect reliably differences in cerebrovascular health across various phenotypes in smaller samples. Though age is a risk factor of COVID-19 severity (Verity et al., 2020) and RSFA (Tsvetanov et al., 2020c), the COVID-19 group effect was not explained by individual's age, and showed only a partial overlap with the effects of age on RSFA in parietal regions (SI Figure 5, Tsvetanov et al., 2020b, 2015)0.
- 295



296

297Figure 1. Source-based cerebrovasculometry for the component differentially expressed between groups: (left)298independent component spatial map reflecting decrease in RSFA values in temporo-parietal regions. (right) Bar plot of subject299scores for patients hospitalised for COVID-19 (red) and control group (green, each circle represents an individual) indicating300higher loading values for patients than controls as informed by two-sample unpaired permutation test (a robust regression

301 was used to down-weight the effects of extreme data points)

medRxiv preprint doi: https://doi.org/10.1101/2022.02.01.22270235; this version posted February 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

### 303 3.3. COVID-19 Severity predicts cerebrovascular impairment

- Using PLS analysis, we identified one significant pair of latent variables (r = 0.584, p = 0.017, based on a null distribution of 10,000 permutations). Variable loadings and subject scores showed a strong relationship between acute COVID-19 Severity and chronic RSFA abnormalities (Figure 2).
- 308 The RSFA latent variable (RSFA-LV) expressed negative loadings in frontal (superior frontal gyrus, middle frontal gyrus, inferior frontal gyrus and portions of the anterior cingulate) and parieto-309 temporal (angular gyrus, supramarginal gyrus, superior temporal gurus, middle temporal gyrus) 310 311 regions. This pattern of COVID-19 Severity-related reduction in RSFA values was mirrored in a voxel-312 wise analysis of RSFA maps and COVID-19 Severity component (SI Figure 5). Positive loadings in the 313 RSFA data appeared to be in postcentral gyrus, calcarine sulcus, cuneus, and lingual gyrus. Increase in the RSFA signal in these regions may reflect increased pulsatility in neighbouring vascular and white 314 matter territories (see SI Figure 5) as reported previously (Makedonov et al., 2016, 2013; Tsvetanov et 315 316 al., 2020b, 2015). This pair of latent variables suggested that patients with higher COVID-19 Severity 317 at acute stage have poorer cerebrovascular function in frontal and temporo-parietal regions at 318 chronic stage. For visualisation purposes we inverted the loading values in Figure 2a so that higher values reflect poorer cerebrovascular function, i.e. higher cerebrovascular burden. 319
- 320 321
  - c | Covid-19 Severity profile a | Cerebrovascular burden map b | subject score relationship Cerebrovascular Burden 0.8 Subject Scores 10 0.4 IL-6 VHO Scale CRP -10 -3 D-Dimer Ferritin Ы APTT Bilirubin Platelets Covid-19 Severity Subject Scores

322 Figure 2. Partial least squares analysis of COVID-19 severity data at acute stage and RSFA-based cerebrovascular 324 burden (CVB) at chronic stage. (panel a) Spatial distribution of parcellated RSFA values where dark to light colours are used 325 for the strength of positive and negative correlations with the COVID-19 Severity profile (panel c). Note that regions with high 326 cerebrovascular burden have low values in RSFA. The scatter plot in the middle panel represents the relationship between 327 subjects scores of RSFA-latent variable and COVID-19 Severity-latent variable identified by partial least squares analysis.

- 328
- To understand whether the relationship between regional RSFA impairment and COVID-19 Severity can be explained by chronic systemic cardiorespiratory dysfunction (see SI method) or covariates of no interest, we performed a second level robust regression analysis. RSFA-LV was entered as the dependent variable. COVID-19 Severity LV and the cardiorespiratory dysfunction

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

component (CRDPCA1, see SI Figure 3) were entered as predictors, while age and sex were modelled as 333 covariates of no interest. All variables were normalised to have a mean of 0 and standard deviation 1. 334 335 Using Wilkinson notation, the regression model took the form: RSFA-LV ~ COVID-19 Severity-LV +  $CRD_{PCA1} + CRD_{PCA2} + Age + Sex$ . COVID-19 Severity was the only significant predictor of RSFA-LV in the 336 337 model (r = 0.471, p = 0.001 and SI Table 1), suggesting that chronic cardiorespiratory dysfunction, age 338 and sex cannot explain fully the relationship between COVID-19 Severity and RSFA abnormality. Interestingly, the unique variance explained by COVID-19 Severity in the regression model was weaker 339 than the variance identified by the PLS analysis (r = 0.584 vs r=0.471 for PLS and MLR analyses) 340 341 suggesting that one or more of the predictors in the model explain partly some of the variance between COVID-19 Severity and RSFA. Permutation-based commonality analysis with 10.000 342 343 permutations (SI Method) confirmed that a portion of the variance between COVID-19 Severity-LV and RSFA-LV was explained by age (12% total, p < 0.001), cardiorespiratory dysfunction component 2 344 345  $(CRD_{PC2}, 3\% \text{ total}, p = 0.009)$ , and shared variance between age and cardiorespiratory dysfunction component 1 (Age,CRD<sub>PCA1</sub>, 20% total, p < 0.001), SI Table 2. COVID-19 Severity-LV remained as the 346 largest unique predictor or RSFA-LV (37% total, p=0.006). 347

348

#### 3.4. Exploratory analysis 349


350 The level of RSFA abnormalities (RSFA-LV) was related to physical, cognitive and mental functioning in an exploratory analysis. RSFA-LV, age and sex were entered as predictors, while 351 cognitive and mental health components (SI Methods) were used as dependent variables in separate 352 353 robust regressions (Model 1: CMH<sub>PCA1</sub> ~ RSFA-LV + age + sex; Model 2: CMH<sub>PCA2</sub> ~ RSFA-LV + age + 354 sex). Model 1 was not significant (p = 0.429), while Model 2 was significant (R2 = 0.294, p = 0.002) with RSFA predicting significantly cognitive and mental health component 2 (r = -0.352, p = 0.014, SI 355 356 Table 3). This indicates that patients with higher RSFA abnormality have worse cognitive function, less functional independence and lower quality of life (social functioning, emotional wellbeing, energy 357 358 dimension). The results did not change in a meaningful way by re-imputing the data (n=5). The 359 findings in Model 2 were confirmed using voxel-wise analysis on RSFA maps, instead of RSFA-LV (SI Figure 7). 360

361 We next assessed the spatial overlap between COVID-19-related cerebrovascular burden maps with existing neurotransmitter and metabolic maps using spatial autocorrelation-preserving permutation 362 testing (Alexander-Bloch et al., 2018). Across 21 candidate maps, we show that the cerebrovascular 363 burden map overlaps with the distribution of serotonin's vasoactive receptor 5-HT1b, aerobic 364 365 glycolysis and to a weaker extent cerebral metabolic rate of glucose in the brain. However, the

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

- 366 regional distribution of RSFA abnormality showed little correlation with the expression of key proteins
- 367 implicated in SARS-CoV-2 cellular attachment, processing and viral defence (Figure 3). Collectively,
- 368 these results demonstrate that the distribution of cerebrovascular impairment related to COVID-19
- 369 severity is aligned with the spatial distribution of receptors and processes involved in the coordination
- 370 of metabolic and vasoreactive responses.
- 371
- 372



### 373

374 Figure 3. Spatial correlation between Covid19 severity-induced cerebrovascular burden map and spatial patterns 375 associated with a range of neurotransmitter receptor/transporters (Hansen et al., 2021b), selective genes relevant to SARS-376 CoV-2 brain entry (ladecola et al., 2020) and brain metabolism parameters (Vaishnavi et al., 2010). Neurotransmitter 377 receptors and transporters were selective to serotonin (5-HT1a, 5-HT1b, 5-HT2a, 5-HT4, 5-HT6, 5-HTT), norepinephrine (NET), 378 histamine (H3), acetylcholine (ACh, A4B2, M1, VAChT), cannabinoid (CB1), opioid (MOR), qlutamate (mGluR5), GABA 379 (GABAa/bz) and dopamine (D1, D2, DAT). Metabolic maps were based on cerebal blood flow (CBF), cerebral blood volume 380 (CBV), cerebral metabolic rate of glucose and oxygen (CMRGlu, CMRO2) and glycemic index (GI). Selective genes relevant to 381 SARS-CoV-2 brain entry included angiotensin converting enzyme-2, ACE2; neuropilin-1, NRP1; neuropilin-2, NRP2, cathepsin-382 B, CTSB; cathepsin-L, CTSL, interferon type 2 receptors, IFNAR2; lymphocyte antigen 6-family member E, LY6E. The spatial 383 maps of 5-HT1b, CMRGlu and Glycemic Index (GI) were significantly correlated with Covid19 severity-induced cerebrovascular 384 burden map (\* p-spin<0.05 (one-sided), \*\*\* p-spin<0.001). See text for more information.


- As a final step, we used normative transcriptomics to identify genes that are normally preferentially expressed in the regions associated with COVID-19-induced cerebrovascular impairment. Regularised-PLS identified one latent component (r=.64, p=0.001, Figure 4a). Using celltype decomposition analysis on a vascular cell-type specific gene sets, we determined the ratio of
- 390 genes in each gene set preferentially expressed in one of eleven cortical cell types: astrocytes, brain

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

endothelial cells, ependymal, macrophage/microglia, meningeal fibroblast, neuron, oligodendrocyte 391 precursors, oligodendrocytes, pericytes, perivascular fibroblast, smooth muscle cells. Gene-sets were 392 393 thresholded to include the top 70% of genes with the highest loadings (Figure 4b), noting that results are consistent across thresholds ranging from 5 to no threshold (Supplementary Figure 8). Dominant 394 genes were significantly more expressed in pericytes, brain endothelial cells and neurons, and 395 396 significantly less expressed in oligodendrocytes. Broadly, we find evidence that areas associated with cerebrovascular impairment are enriched in for genetic signal related to neuron support (pericytes, 397 endothelial cells and perineuronal oligodendrocytes) and neurons themselves. This dichotomy is 398 399 consistent with the observations from the spatial overlap analysis.

400



401

402 Figure 4. a, Spatial map in the transcriptome data related to the COVID-19-induced cerebrovascular burden map 403 (CVB). b, Cell-type decomposition was used to identify cell-type enrichment based on extent to which genes expressed the 404 transcriptome map in a. Gene sets for each cell-type was constructed by thresholding the top 70% of genes with greatest 405 loadings. Note that results were consistent across a range of thresholds, ranging from 10% to no threshold, SI Figure 8. The 406 ratio of genes in each gene set preferentially expressed in eleven distinct cell-types (circles) is shown against their null 407 distribution of a model with random selection of all genes (10.000 permutations, \*p-value < 0.05). For example, pericyte's 408 ratio is calculated from the number of genes preferentially expressed in pericytes divided by the total number of genes. Cell 409 type-specificity of genes is described elsewhere (Yang et al., 2021) Astro – astrocytes, BEC – brain endothelial cells, Epend – 410 ependymal, MacMic – macrophage/microalia, Mfibro – meningeal fibroblast, Neuron – neuron, OPC – oligodendrocyte 411 precursor cells, Oligo – oligodendrocytes, Peri – pericytes, Pfibro – perivascular fibroblast, SMC – smooth muscle cells

412

# 413 4. Discussion

414

We show that abnormalities in cerebral microvascular function, measured using resting state fluctuation amplitudes (RSFA), persist many months after hospitalisation for acute COVID-19. The location of these abnormalities in lateral frontal and temporoparietal regions aligns partly with cerebrovascular dysfunction reported in association with ageing (Tsvetanov et al., 2020b, 2015),

419 preclinical Alzheimer's disease (Millar et al., 2020a) and systemic cardiovascular health (Tsvetanov et

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

al., 2020b).These post-COVID-19 effects were observed over and above age. They are related to
severity of the acute illness and the host response in the acute stage. These effects also relate to the
post-COVID-19 cognitive function, common indices of mental health, and quality of life at an average
of six months after hospitalisation.

424 In exploratory analysis, we found overlap between the regional distribution of this cerebrovascular impairment and spatial distribution of the vasoreactive receptor 5-HT1b and regions 425 426 with high metabolic demands. 5-HT1b receptor is the dominant contractile 5-HT receptor in cerebral 427 arteries (Barnes et al., 2021; Nilsson et al., 1999), acting on vasoconstriction by contracting smooth 428 muscle endothelial smooth muscle directly or as moderator of other vasoconstrictors. Distinct from 429 its effects on vascular tone, the presynaptic 5-HT1b receptor also has an important microvascular 430 anti-inflammatory role, both in the cerebrovascular bed and more generally. Further, its loss has 431 been implicated in progressive cognitive loss and abnormal modulation through descending 432 serotoninergic outputs (Gharishvandi et al., 2020; Heijmans et al., 2021; Mitsikostas et al., 2002; 433 Sibille et al., 2007), which may be relevant for late sequelae after COVID-19.

434 The overlap of cerebrovascular impairment with the regional distribution of aerobic glycolysis 435 and glucose metabolism is spatially concordant with previous reports of hypometabolism in the subacute phase of COVID-19 (Hosp et al., 2021) and neurodegeneration (Vlassenko et al., 2010). This 436 437 discussion provides a potential link between cerebrovascular impairment and metabolic dysfunction 438 in frontoparietal regions, which could provide important insights regarding the mechanisms of late 439 neurocognitive dysfunction following COVID-19 infection. Future work should establish whether changes to the microvasculature lead to hypometabolism (Shi et al., 2016) or the vulnerability of brain 440 physiology in chronic phase is due to hypoxic and hypometabolic exposure in the subacute phase 441 442 (Vestergaard et al., 2020). Collectively, these results demonstrate that the distribution of chronic cerebrovascular impairment related to COVID-19 severity maps to the spatial distribution of 443 444 processes involved in coordinating metabolic and vasoregulatory responses associated with changes in brain function and cognition. 445

We also tested whether genes highly expressed in regions with COVID-19-induced cerebrovascular change are preferentially expressed in specific cell types using a molecular atlas of human brain vasculature (Yang et al., 2021). Dominant genes were overexpressed in perycites, brain endothelial cells and neurons, but underexpressed in oligodendrocytes. The evidence that genes implicated are enriched in pericytes and endothelial cells is particularly interesting. Brain endothelial cells are susceptible to direct SARS-CoV-2 infection through flow-dependent expression of ACE2. The SARS-

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

CoV-2 S protein binding triggers a gene expression profile that may compromise the neurovascular
interface (Kaneko et al., 2021). On the abluminal aspect of the neurovascular interface, pericytes
express abundantly the angiotensin-converting enzyme-2 (ACE2) receptor (He et al., 2020). The
expression can be increased with by exposure to the viral S protein, and importantly, potentiated in
combination with hypoxia (Khaddaj-Mallat et al., 2021), a mechanism which could account for the
modulation of RSFA abnormality by disease severity in our cohort.
Given this biological context the correlation of RSFA abnormalities with disease severity is

459 open to two potential interpretations. One possibility is that these changes in cerebrovascular 460 regulatory integrity are the consequence of direct viral invasion; while the other is that these 461 abnormalities are a consequence of the inflammatory host response, which is a consequence of, but 462 may not scale precisely with, viral infection. Spatial correlation of RSFA abnormality with the expression of ACE2 and Neuropilin-1, or of genes involved in cellular responses to viral invasion would 463 464 have provided supportive evidence of a role for direct viral infection as a mechanism, but we were unable to demonstrate such a correlation. This negative finding favours the explanation that host 465 inflammatory responses may be drivers in this context, and merit further investigation as mechanisms 466 467 of late cerebrovascular regulatory dysfunction. It is important to acknowledge that our correlations with regional gene expression are based on expression patterns in normal brain, and that these 468 469 expression patterns may be substantially altered by the inflammatory milieu that prevails in the 470 context of COVID-19. Consequently, direct examination gene expression patterns in late COVID-19 survivors would provide additional insights. 471

472

473 Our study has several limitations. We are limited by the relatively small sample size, and by 474 the absence of longitudinal imaging data. We also do not draw any causal inferences from the 475 associations we observe. However, the demonstration of functional microvascular abnormalities 476 following COVID-19 is important to understand the potential mechanisms of persistent cognitive and mental health problems. The association of microvascular abnormalities with late outcomes of 477 478 relevance to patients, and the fact that they represent an easily accessible biomarker, suggest both a 479 potential therapeutic target and/or a biomarker of treatment effect in interventional studies. It remains to be shown whether the localisation of RSFA abnormalities to regions rich in 5HT-1b 480 receptors is a consequence of overactivity of these receptors (resulting in low cerebral blood flow), 481 underactivity or loss of these receptors (resulting in vasoparalysis and/or inflammation), or a 482 483 manifestation of flow-metabolism mismatching with inadequate substrate and oxygen delivery. This is relevant as potential therapeutic agents that are available to modulate both 5HT-1b function (Barnes 484 485 et al 2021) and inflammatory response (Zhang et al., 2020) (Group et al., 2021b; Zhang et al., 2020).

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

### 486

In summary, we demonstrate that the severity of acute COVID-19 predicts cerebrovascular 487 488 impairment six months later. The cerebrovascular abnormality was associated with worse cognitive function, mental health, functional recovery, and quality of life months after hospitalisation. Localised 489 490 across lateral frontotemporoparietal regions, we show that its genetic signature shapes the 491 composition of cell-types and metabolism. Collectively, these results implicate the COVID-19-related vulnerability of brain systems differentially relying on diverse physiology and cell biology in support of 492 their functional specialisation. 493 494 5. Acknowledgements 495 496 497 This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), 498 NIHR funding to the NIHR BioResource (RG94028 & RG85445), Guarantors of Brain (G101149), Wellcome Trust (220258), Medical Research Council (SUAG/051G101400; and SUAG/010 RG91365), 499 500 and by the Addenbrookes Charitable Trust. We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their 501 502 contribution. We thank the National Institute for Health Research, NHS Blood and Transplant, and 503 Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are 504 those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health 505 and Social Care. 506 507 508 509

#### 6. Conflicts of interest 510

511 All authors have no conflicts of interest. Untreated to this there are several disclosures.

512

- VFJN holds a grant from Roche Pharmaceuticals on proteomic biomarkers in traumatic brain injury 513
- 514 and reports personal fees from Neurodiem.

- 516 ETB serves on the scientific advisory board of Sosei Hepatares and as a consultant for GSK.
- 517

It is made available under a CC-BY-NC-ND 4.0 Ir COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

518	JBR serves as an associate editor to Brain and is a non-remunerated trustee of the Guarantors of
519	Brain, Darwin College and the PSP Association (UK). He provides consultancy to Asceneuron, Biogen,
520	UCB and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the
521	Dementias Platform UK.
522	
523	DKM reports grants, personal fees, and nonfinancial support from GlaxoSmithKline Ltd.; grants,
524	personal fees, and other from NeuroTrauma Sciences; grants and personal fees from Integra Life

525 Sciences; personal fees from Pfizer Ltd.; grants and personal fees from Lantmannen AB; from Calico

526 Ltd.; personal fees from Pressura Neuro Ltd.; and others from Cortirio Ltd., outside the submitted

527 work.

528

# 529 7. References

- Agarwal, S., Hanzhang, L., Pillai, J.J., 2017. Value of Frequency Domain Resting-State Functional
- 532 Magnetic Resonance Imaging Metrics Amplitude of Low-Frequency Fluctuation and Fractional
- 533 Amplitude of Low-Frequency Fluctuation in the Assessment of Brain Tumor-Induced
- 534 Neurovascular Uncoupling. https://home.liebertpub.com/brain 7, 382–389.
- 535 https://doi.org/10.1089/BRAIN.2016.0480
- Agarwal, S., Sair, H., Gujar, S., Hua, J., Lu, H., Pillai, J., 2019. Functional Magnetic Resonance Imaging
   Activation Optimization in the Setting of Brain Tumor-Induced Neurovascular Uncoupling Using
- 538 Resting-State Blood Oxygen Level-Dependent Amplitude of Low Frequency Fluctuations. Brain
- 539 connectivity 9, 241–250. https://doi.org/10.1089/BRAIN.2017.0562
- Ainslie, P.N., Ashmead, J.C., Ide, K., Morgan, B.J., Poulin, M.J., 2005. Differential responses to CO2 and
- 541 sympathetic stimulation in the cerebral and femoral circulations in humans. The Journal of
- 542 physiology 566, 613–24. https://doi.org/10.1113/jphysiol.2005.087320
- 543 Alexander-Bloch, A.F., Shou, H., Liu, S., Satterthwaite, T.D., Glahn, D.C., Shinohara, R.T., Vandekar,
- 544 S.N., Raznahan, A., 2018. On testing for spatial correspondence between maps of human brain
- 545 structure and function. NeuroImage 178, 540.
- 546 https://doi.org/10.1016/J.NEUROIMAGE.2018.05.070
- 547 Arnatkevičiūtė, A., Fulcher, B.D., Fornito, A., 2019. A practical guide to linking brain-wide gene
- 548 expression and neuroimaging data. NeuroImage 189, 353–367.
- 549 https://doi.org/10.1016/J.NEUROIMAGE.2019.01.011

medRxiv preprint doi: https://doi.org/10.1101/2022.02.01.22270235; this version posted February 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

Asakura, H., Ogawa, H., 2020. COVID-19-associated coagulopathy and disseminated intravascular 550 551 coagulation. International Journal of Hematology 2020 113:1 113, 45-57. 552 https://doi.org/10.1007/S12185-020-03029-Y 553 Bangash, M.N., Patel, J., Parekh, D., 2020. COVID-19 and the liver: little cause for concern. The Lancet 554 Gastroenterology & Hepatology 5, 529-530. https://doi.org/10.1016/S2468-1253(20)30084-4 555 Barnes, N.M., Ahern, G.P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., 556 Cunningham, K.A., Fone, K.C., Gershon, M., di Giovanni, G., Goodfellow, N.M., Halberstadt, A.L., Hartley, R.M., Hassaine, G., Herrick-Davis, K., Hovius, R., Lacivita, E., Lambe, E.K., Leopoldo, M., 557 Levy, F.O., Lummis, S.C.R., Marin, P., Maroteaux, L., McCreary, A.C., Nelson, D.L., Neumaier, J.F., 558 559 Newman-Tancredi, A., Nury, H., Roberts, A., Roth, B.L., Roumier, A., Sanger, G.J., Teitler, M., 560 Sharp, T., Villalón, C.M., Vogel, H., Watts, S.W., Hover, D., 2021. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology 561 562 and Function. Pharmacological reviews 73, 310–520. https://doi.org/10.1124/PR.118.015552 Becker, R.C., 2020. COVID-19-associated vasculitis and vasculopathy. Journal of Thrombosis and 563 Thrombolysis 2020 50:3 50, 499–511. https://doi.org/10.1007/S11239-020-02230-4 564 Birn, R.M., Diamond, J.B., Smith, M. a. Bandettini, P. a. 2006. Separating respiratory-variation-related 565 566 fluctuations from neuronal-activity-related fluctuations in fMRI. NeuroImage 31, 1536–48. 567 https://doi.org/10.1016/j.neuroimage.2006.02.048 568 Blankertz, B., Lemm, S., Treder, M., Haufe, S., Müller, K.-R., 2011. Single-trial analysis and classification 569 of ERP components--a tutorial. NeuroImage 56, 814–25. https://doi.org/10.1016/j.neuroimage.2010.06.048 570 571 Bois, R.M. du, Weycker, D., Albera, C., Bradford, W.Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, 572 P.W., Sahn, S.A., Szwarcberg, J., Thomeer, M., Valeyre, D., Talmadge E. King, Jr., 2012. Six-573 Minute-Walk Test in Idiopathic Pulmonary Fibrosis. https://doi.org/10.1164/rccm.201007-574 1179OC 183, 1231–1237. https://doi.org/10.1164/RCCM.201007-1179OC Brandes, R.P., Fleming, I., Busse, R., 2005. Endothelial aging. Cardiovascular Research. 575 576 https://doi.org/10.1016/j.cardiores.2004.12.027 577 Chen, X., Laurent, S., Onur, O.A., Kleineberg, N.N., Fink, G.R., Schweitzer, F., Warnke, C., 2020. A systematic review of neurological symptoms and complications of COVID-19. Journal of 578 579 Neurology 2020 268:2 268, 392–402. https://doi.org/10.1007/S00415-020-10067-3 Crapo, R.O., Casaburi, R., Coates, A.L., Enright, P.L., MacIntyre, N.R., McKay, R.T., Johnson, D., Wanger, 580 581 J.S., Zeballos, R.J., Bittner, V., Mottram, C., 2012. ATS Statement: Guidelines for the six-minute 582 walk test. https://doi.org/10.1164/ajrccm.166.1.at1102 166, 111–117. 583 https://doi.org/10.1164/AJRCCM.166.1.AT1102

medRxiv preprint doi: https://doi.org/10.1101/2022.02.01.22270235; this version posted February 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 severity and cerebrovascular burden

- Eriksson, M., Appelros, P., Norrving, B., Terént, A., Stegmayr, B., 2007. Assessment of Functional 584 585 Outcome in a National Quality Register for Acute Stroke. Stroke 38, 1384–1386. 586 https://doi.org/10.1161/01.STR.0000260102.97954.9C Friston, K.J., Ashburner, J., Kiebel, S., Nichols, T., Penny, W.D., 2007. Statistical parametric mapping : 587 588 the analysis of funtional brain images. Elsevier Academic Press. https://doi.org/10.1016/B978-0-589 12-372560-8.X5000-1 590 Fulcher, B.D., Arnatkeviciute, A., Fornito, A., 2021. Overcoming false-positive gene-category enrichment in the analysis of spatially resolved transcriptomic brain atlas data. Nature 591 592 Communications 2021 12:1 12, 1–13. https://doi.org/10.1038/s41467-021-22862-1 Gao, Y.-Z., Zhang, J.-J., Liu, H., Wu, G.-Y., Xiong, L., Shu, M., 2013. Regional cerebral blood flow and 593 594 cerebrovascular reactivity in Alzheimer's disease and vascular dementia assessed by arterial 595 spinlabeling magnetic resonance imaging. Current neurovascular research 10, 49–53. 596 Garrett, D.D., Lindenberger, U., Hoge, R.D., Gauthier, C.J., 2017. Age differences in brain signal 597 variability are robust to multiple vascular controls. Scientific Reports 7, 10149. https://doi.org/10.1038/s41598-017-09752-7 598 Geerligs, L., Tsvetanov, K.A., Cam-Can, Henson, R.N., 2017, Challenges in measuring individual 599 600 differences in functional connectivity using fMRI: The case of healthy aging. Human Brain 601 Mapping. https://doi.org/10.1002/hbm.23653 602 Gharishvandi, F., Abdollahi, A., Shafaroodi, H., Mohammad Jafari, R., Pasalar, P., Dehpour, A.R., 2020. Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in 603 intestinal ischemia/reperfusion in rats. European journal of pharmacology 882. 604 605 https://doi.org/10.1016/J.EJPHAR.2020.173265 Glasser, M.F., Coalson, T.S., Robinson, E.C., Hacker, C.D., Harwell, J., Yacoub, E., Ugurbil, K., 606 607 Andersson, J., Beckmann, C.F., Jenkinson, M., Smith, S.M., Van Essen, D.C., 2016. A multi-modal parcellation of human cerebral cortex. Nature 2016 536:7615 536, 171–178. 608 https://doi.org/10.1038/nature18933 609 610 Glover, G.H., Shmueli, K., van Gelderen, P., de Zwart, J. a, Horovitz, S.G., Fukunaga, M., Jansma, J.M.,
- 611 Duyn, J.H., 2007. Low-frequency fluctuations in the cardiac rate as a source of variance in the 612 resting-state fMRI BOLD signal. NeuroImage 38, 306–20.
- 613 https://doi.org/10.1016/j.neuroimage.2007.07.037
- Group, T.W.R.E.A. for C.-19 T. (REACT) W., Domingo, P., Mur, I., Mateo, G.M., Gutierrez, M. del M.,
- Pomar, V., Benito, N. de, Corbacho, N., Herrera, S., Millan, L., Muñoz, J., Malouf, J., Molas, M.E.,
- Asensi, V., Horcajada, J.P., Estrada, V., Gutierrez, F., Torres, F., Perez-Molina, J.A., Fortun, J.,
- Villar, L.M., Hohenthal, U., Marttila, H., Vuorinen, T., Nordberg, M., Valtonen, M., Frigault, M.J.,

It is made available under a CC-BY-NC-ND 4.0 Interna COVID-19 severity and cerebrovascular burden

618	Mansour, M.K., Patel, N.J., Fernandes, A., Harvey, L., Foulkes, A.S., Healy, B.C., Shah, R., Bensaci,
619	A.M., Woolley, A.E., Nikiforow, S., Lin, N., Sagar, M., Shrager, H., Huckins, D.S., Axelrod, M.,
620	Pincus, M.D., Fleisher, J., Lampa, J., Nowak, P., Vesterbacka, J.C., Rasmuson, J., Skorup, P., Janols,
621	H., Niward, K.F., Chatzidionysiou, K., Asgeirsson, H., Parke, Å., Blennow, O., Svensson, AK.,
622	Aleman, S., Sönnerborg, A., Henter, JI., Horne, A.C., Al-Beidh, F., Angus, D., Annane, D., Arabi,
623	Y., Beane, A., Berry, S., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Cheng,
624	A., Cove, M., Jong, M. de, Derde, L., Estcourt, L., Goossens, H., Gordon, A., Green, C., Haniffa, R.,
625	Ichihara, N., Lamontagne, F., Lawler, P., Litton, E., Marshall, J., McArthur, C., McAuley, D.,
626	McGuinness, S., McVerry, B., Montgommery, S., Mouncey, P., Murthy, S., Nichol, A., Parke, R.,
627	Parker, J., Reyes, F., Rowan, K., Saito, H., Santos, M., Seymour, C., Shankar-Hari, M., Turgeon, A.,
628	Turner, A., Bentum-Puijk, W. van, Veerdonk, F. van de, Webb, S., Zarychanski, R., Baillie, J.K.,
629	Beasley, R., Cooper, N., Fowler, R., Galea, J., Hills, T., King, A., Morpeth, S., Netea, M.,
630	Ogungbenro, K., Pettila, V., Tong, S., Uyeki, T., Youngstein, T., Higgins, A., Lorenzi, E., Berry, L.,
631	Salama, C., Rosas, I.O., Ruiz-Antorán, B., Rubio, E.M., Martínez, A.R., Esteban, J.C., Solá, C.A.,
632	Pizov, R., Sanz, J.S., Abad-Santos, F., Bautista-Hernández, A., García-Fraile, L., Barrios, A., Liarte,
633	Á.G., Pérez, T.A., Rodríguez-García, S.C., Mejía-Abril, G., Prieto, J.C., Leon, R., VEIGA, V.C.,
634	SCHEINBERG, P., FARIAS, D.L.C., PRATS, J.G., CAVALCANTI, A.B., MACHADO, F.R., ROSA, R.G.,
635	BERWANGER, O., AZEVEDO, L.C.P., LOPES, R.D., DOURADO, L.K., CASTRO, C.G., ZAMPIERI, F.G.,
636	AVEZUM, A., LISBOA, T.C., ROJAS, S.S.O., COELHO, J.C., LEITE, R.T., CARVALHO, J.C., ANDRADE,
637	L.E.C., SANDES, A.R., PINTÃO, M.C.T., SANTOS, S. v., ALMEIDA, T.M.L., COSTA, A.N., GEBARA,
638	O.C.E., FREITAS, F.G.R., PACHECO, E.S., MACHADO, D.J.B., MARTIN, J., CONCEIÇÃO, F.G.,
639	SIQUEIRA, S.R.R., DAMIANI, L.P., ISHIHARA, L.M., SCHNEIDER, D., SOUZA, D. de, Hermine, O.,
640	Mariette, X., Tharaux, P.L., Rigon, M.R., Porcher, R., Ravaud, P., Azoulay, E., Cadranel, J.,
641	Emmerich, J., Fartoukh, M., Guidet, B., Humbert, M., Lacombe, K., Mahevas, M., Pene, F.,
642	Pourchet-Martinez, V., Schlemmer, F., Tibi, A., Yazdanpanah, Y., Dougados, M., Bureau, S.,
643	Horby, P.W., Landray, M.J., Baillie, K.J., Buch, M.H., Chappell, L.C., Day, J.N., Faust, S.N., Haynes,
644	R., Jaki, T., Jeffery, K., Juszczak, E., Lim, W.S., Mafham, M., Montgomery, A., Mumford, A.,
645	Thwaites, G., Kamarulzaman, A., Omar, S.F.S., Ponnampalavanar, S., Azwa, R.I.S.R., Wong, P.L.,
646	Kukreja, A., Ong, H.C., Sulaiman, H., Basri, S., Ng, R.X., Johari, B.M., Rajasuriar, R., Chong, M.L.,
647	Neelamegam, M., Mansor, S.M.S., Zulhaimi, N.S., Lee, C.S., Altice, F., Price, C., Malinis, M.,
648	Hasan, M.S., Wong, C.K., Chidambaram, S., Misnan, N.A., Thabit, A.A.M., Sim, B., Bidin, F.N.,
649	Rahim, M.A.H.M.A., Saravanamuttu, S., Tuang, W.X., Gani, Y.M., Thangavelu, S., Tay, K.H.,
650	Ibrahim, N.M., Halid, L.A., Tan, K.T., Mukri, M.N.A., Arip, M., Koh, H.M., Badaruddin, S.N.A.S.,
651	Sureja, L.R., Chun, G.Y., TORRE-CISNEROS, J., MERCHANTE, N., LEON, R., CARCEL, S., GARRIDO,

COVID-19 severity and cerebrovascular burden

652	J.C., Galun, E., Soriano, A., Martínez, J.A., Castán, C., Paredes, R., Dalmau, D., Carbonell, C.,
653	Espinosa, G., Castro, P., Muñóz, J., Almuedo, A., Prieto, S., Pacheco, I., Ratain, M., Pisano, J.,
654	Strek, M., Adegunsoye, A., Karrison, T., Jozefien, D., F.A., V.D.K., Elisabeth, D.L., Cedric, B.,
655	Bastiaan, M., Shankar-Hari, M., Vale, C.L., Godolphin, P.J., Fisher, D., Higgins, J.P.T., Spiga, F.,
656	Savović, J., Tierney, J., Baron, G., Benbenishty, J.S., Berry, L.R., Broman, N., Cavalcanti, A.B.,
657	Colman, R., Buyser, S.L. de, Derde, L.P.G., Domingo, P., Omar, S.F., Fernandez-Cruz, A., Feuth, T.,
658	Garcia, F., Garcia-Vicuna, R., Gonzalez-Alvaro, I., Gordon, A.C., Haynes, R., Hermine, O., Horby,
659	P.W., Horick, N.K., Kumar, K., Lambrecht, B.N., Landray, M.J., Leal, L., Lederer, D.J., Lorenzi, E.,
660	Mariette, X., Merchante, N., Misnan, N.A., Mohan, S. v., Nivens, M.C., Oksi, J., Perez-Molina, J.A.,
661	Pizov, R., Porcher, R., Postma, S., Rajasuriar, R., Ramanan, A. v., Ravaud, P., Reid, P.D., Rutgers,
662	A., Sancho-Lopez, A., Seto, T.B., Sivapalasingam, S., Soin, A.S., Staplin, N., Stone, J.H., Strohbehn,
663	G.W., Sunden-Cullberg, J., Torre-Cisneros, J., Tsai, L.W., Hoogstraten, H. van, Meerten, T. van,
664	Veiga, V.C., Westerweel, P.E., Murthy, S., Diaz, J. v., Marshall, J.C., Sterne, J.A.C., 2021a.
665	Association Between Administration of IL-6 Antagonists and Mortality Among Patients
666	Hospitalized for COVID-19: A Meta-analysis. JAMA 326, 499–518.
667	https://doi.org/10.1001/JAMA.2021.11330
668	Group, T.W.R.E.A. for C19 T. (REACT) W., Domingo, P., Mur, I., Mateo, G.M., Gutierrez, M. del M.,
669	Pomar, V., Benito, N. de, Corbacho, N., Herrera, S., Millan, L., Muñoz, J., Malouf, J., Molas, M.E.,
670	Asensi, V., Horcajada, J.P., Estrada, V., Gutierrez, F., Torres, F., Perez-Molina, J.A., Fortun, J.,
671	Villar, L.M., Hohenthal, U., Marttila, H., Vuorinen, T., Nordberg, M., Valtonen, M., Frigault, M.J.,
672	Mansour, M.K., Patel, N.J., Fernandes, A., Harvey, L., Foulkes, A.S., Healy, B.C., Shah, R., Bensaci,
673	A.M., Woolley, A.E., Nikiforow, S., Lin, N., Sagar, M., Shrager, H., Huckins, D.S., Axelrod, M.,
674	Pincus, M.D., Fleisher, J., Lampa, J., Nowak, P., Vesterbacka, J.C., Rasmuson, J., Skorup, P., Janols,
675	H., Niward, K.F., Chatzidionysiou, K., Asgeirsson, H., Parke, Å., Blennow, O., Svensson, AK.,
676	Aleman, S., Sönnerborg, A., Henter, JI., Horne, A.C., Al-Beidh, F., Angus, D., Annane, D., Arabi,
677	Y., Beane, A., Berry, S., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Cheng,
678	A., Cove, M., Jong, M. de, Derde, L., Estcourt, L., Goossens, H., Gordon, A., Green, C., Haniffa, R.,
679	Ichihara, N., Lamontagne, F., Lawler, P., Litton, E., Marshall, J., McArthur, C., McAuley, D.,
680	McGuinness, S., McVerry, B., Montgommery, S., Mouncey, P., Murthy, S., Nichol, A., Parke, R.,
681	Parker, J., Reyes, F., Rowan, K., Saito, H., Santos, M., Seymour, C., Shankar-Hari, M., Turgeon, A.,
682	Turner, A., Bentum-Puijk, W. van, Veerdonk, F. van de, Webb, S., Zarychanski, R., Baillie, J.K.,
683	Beasley, R., Cooper, N., Fowler, R., Galea, J., Hills, T., King, A., Morpeth, S., Netea, M.,
684	Ogungbenro, K., Pettila, V., Tong, S., Uyeki, T., Youngstein, T., Higgins, A., Lorenzi, E., Berry, L.,
685	Salama, C., Rosas, I.O., Ruiz-Antorán, B., Rubio, E.M., Martínez, A.R., Esteban, J.C., Solá, C.A.,

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

Pizov, R., Sanz, J.S., Abad-Santos, F., Bautista-Hernández, A., García-Fraile, L., Barrios, A., Liarte, 686 Á.G., Pérez, T.A., Rodríguez-García, S.C., Mejía-Abril, G., Prieto, J.C., Leon, R., VEIGA, V.C., 687 688 SCHEINBERG, P., FARIAS, D.L.C., PRATS, J.G., CAVALCANTI, A.B., MACHADO, F.R., ROSA, R.G., 689 BERWANGER, O., AZEVEDO, L.C.P., LOPES, R.D., DOURADO, L.K., CASTRO, C.G., ZAMPIERI, F.G., 690 AVEZUM, A., LISBOA, T.C., ROJAS, S.S.O., COELHO, J.C., LEITE, R.T., CARVALHO, J.C., ANDRADE, 691 L.E.C., SANDES, A.R., PINTÃO, M.C.T., SANTOS, S. v., ALMEIDA, T.M.L., COSTA, A.N., GEBARA, 692 O.C.E., FREITAS, F.G.R., PACHECO, E.S., MACHADO, D.J.B., MARTIN, J., CONCEIÇÃO, F.G., SIQUEIRA, S.R.R., DAMIANI, L.P., ISHIHARA, L.M., SCHNEIDER, D., SOUZA, D. de, Hermine, O., 693 694 Mariette, X., Tharaux, P.L., Rigon, M.R., Porcher, R., Ravaud, P., Azoulay, E., Cadranel, J., 695 Emmerich, J., Fartoukh, M., Guidet, B., Humbert, M., Lacombe, K., Mahevas, M., Pene, F., 696 Pourchet-Martinez, V., Schlemmer, F., Tibi, A., Yazdanpanah, Y., Dougados, M., Bureau, S., 697 Horby, P.W., Landray, M.J., Baillie, K.J., Buch, M.H., Chappell, L.C., Day, J.N., Faust, S.N., Haynes, 698 R., Jaki, T., Jeffery, K., Juszczak, E., Lim, W.S., Mafham, M., Montgomery, A., Mumford, A., Thwaites, G., Kamarulzaman, A., Omar, S.F.S., Ponnampalavanar, S., Azwa, R.I.S.R., Wong, P.L., 699 700 Kukreja, A., Ong, H.C., Sulaiman, H., Basri, S., Ng, R.X., Johari, B.M., Rajasuriar, R., Chong, M.L., 701 Neelamegam, M., Mansor, S.M.S., Zulhaimi, N.S., Lee, C.S., Altice, F., Price, C., Malinis, M., 702 Hasan, M.S., Wong, C.K., Chidambaram, S., Misnan, N.A., Thabit, A.A.M., Sim, B., Bidin, F.N., 703 Rahim, M.A.H.M.A., Saravanamuttu, S., Tuang, W.X., Gani, Y.M., Thangavelu, S., Tay, K.H., 704 Ibrahim, N.M., Halid, L.A., Tan, K.T., Mukri, M.N.A., Arip, M., Koh, H.M., Badaruddin, S.N.A.S., 705 Sureja, L.R., Chun, G.Y., TORRE-CISNEROS, J., MERCHANTE, N., LEON, R., CARCEL, S., GARRIDO, J.C., Galun, E., Soriano, A., Martínez, J.A., Castán, C., Paredes, R., Dalmau, D., Carbonell, C., 706 707 Espinosa, G., Castro, P., Muñóz, J., Almuedo, A., Prieto, S., Pacheco, I., Ratain, M., Pisano, J., 708 Strek, M., Adegunsove, A., Karrison, T., Jozefien, D., F.A., V.D.K., Elisabeth, D.L., Cedric, B., 709 Bastiaan, M., Shankar-Hari, M., Vale, C.L., Godolphin, P.J., Fisher, D., Higgins, J.P.T., Spiga, F., 710 Savović, J., Tierney, J., Baron, G., Benbenishty, J.S., Berry, L.R., Broman, N., Cavalcanti, A.B., Colman, R., Buyser, S.L. de, Derde, L.P.G., Domingo, P., Omar, S.F., Fernandez-Cruz, A., Feuth, T., 711 712 Garcia, F., Garcia-Vicuna, R., Gonzalez-Alvaro, I., Gordon, A.C., Haynes, R., Hermine, O., Horby, 713 P.W., Horick, N.K., Kumar, K., Lambrecht, B.N., Landray, M.J., Leal, L., Lederer, D.J., Lorenzi, E., 714 Mariette, X., Merchante, N., Misnan, N.A., Mohan, S. v., Nivens, M.C., Oksi, J., Perez-Molina, J.A., 715 Pizov, R., Porcher, R., Postma, S., Rajasuriar, R., Ramanan, A. v., Ravaud, P., Reid, P.D., Rutgers, A., Sancho-Lopez, A., Seto, T.B., Sivapalasingam, S., Soin, A.S., Staplin, N., Stone, J.H., Strohbehn, 716 717 G.W., Sunden-Cullberg, J., Torre-Cisneros, J., Tsai, L.W., Hoogstraten, H. van, Meerten, T. van, 718 Veiga, V.C., Westerweel, P.E., Murthy, S., Diaz, J. v., Marshall, J.C., Sterne, J.A.C., 2021b. 719 Association Between Administration of IL-6 Antagonists and Mortality Among Patients

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

720	Hospitalized for COVID-19: A Meta-analysis. JAMA 326, 499–518.
721	https://doi.org/10.1001/JAMA.2021.11330
722	Hallquist, M.N., Hwang, K., Luna, B., 2013. The nuisance of nuisance regression: spectral
723	misspecification in a common approach to resting-state fMRI preprocessing reintroduces noise
724	and obscures functional connectivity. NeuroImage 82, 208–25.
725	https://doi.org/10.1016/j.neuroimage.2013.05.116
726	Hanafi, R., Roger, PA., Perin, B., Kuchcinski, G., Deleval, N., Dallery, F., Michel, D., Hacein-Bey, L.,
727	Pruvo, JP., Outteryck, O., Constans, JM., 2020. COVID-19 Neurologic Complication with CNS
728	Vasculitis-Like Pattern. American Journal of Neuroradiology 41, 1384–1387.
729	https://doi.org/10.3174/AJNR.A6651
730	Hansen, J.Y., Markello, R.D., Vogel, J.W., Seidlitz, J., Bzdok, D., Misic, B., 2021a. Mapping gene
731	transcription and neurocognition across human neocortex. Nature Human Behaviour 2021 5:9 5,
732	1240–1250. https://doi.org/10.1038/s41562-021-01082-z
733	Hansen, J.Y., Shafiei, G., Markello, R.D., Smart, K., Cox, S.M.L., Wu, Y., Gallezot, JD., Aumont, É.,
734	Servaes, S., Scala, S.G., DuBois, J.M., Wainstein, G., Bezgin, G., Funck, T., Schmitz, T.W., Spreng,
735	R.N., Soucy, JP., Baillet, S., Guimond, S., Hietala, J., Bédard, MA., Leyton, M., Kobayashi, E.,
736	Rosa-Neto, P., Palomero-Gallagher, N., Shine, J.M., Carson, R.E., Tuominen, L., Dagher, A., Misic,
737	B., 2021b. Mapping neurotransmitter systems to the structural and functional organization of
738	the human neocortex. bioRxiv 2021.10.28.466336. https://doi.org/10.1101/2021.10.28.466336
739	Hawrylycz, M.J., Lein, E.S., Guillozet-Bongaarts, A.L., Shen, E.H., Ng, L., Miller, J.A., van de Lagemaat,
740	L.N., Smith, K.A., Ebbert, A., Riley, Z.L., Abajian, C., Beckmann, C.F., Bernard, A., Bertagnolli, D.,
741	Boe, A.F., Cartagena, P.M., Mallar Chakravarty, M., Chapin, M., Chong, J., Dalley, R.A., Daly, B.D.,
742	Dang, C., Datta, S., Dee, N., Dolbeare, T.A., Faber, V., Feng, D., Fowler, D.R., Goldy, J., Gregor,
743	B.W., Haradon, Z., Haynor, D.R., Hohmann, J.G., Horvath, S., Howard, R.E., Jeromin, A., Jochim,
744	J.M., Kinnunen, M., Lau, C., Lazarz, E.T., Lee, C., Lemon, T.A., Li, L., Li, Y., Morris, J.A., Overly, C.C.,
745	Parker, P.D., Parry, S.E., Reding, M., Royall, J.J., Schulkin, J., Sequeira, P.A., Slaughterbeck, C.R.,
746	Smith, S.C., Sodt, A.J., Sunkin, S.M., Swanson, B.E., Vawter, M.P., Williams, D., Wohnoutka, P.,
747	Ronald Zielke, H., Geschwind, D.H., Hof, P.R., Smith, S.M., Koch, C., Grant, S.G.N., Jones, A.R.,
748	2012. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature
749	489, 391–399. https://doi.org/10.1038/NATURE11405
750	He, L., Mäe, M.A., Muhl, L., Sun, Y., Pietilä, R., Nahar, K., Liébanas, E.V., Fagerlund, M.J., Oldner, A.,
751	Liu, J., Genové, G., Zhang, L., Xie, Y., Leptidis, S., Mocci, G., Stritt, S., Osman, A., Anisimov, A.,
752	Hemanthakumar, K.A., Räsänen, M., Mirabeau, O., Hansson, E., Björkegren, J., Vanlandewijck,

M., Blomgren, K., Mäkinen, T., Peng, X.R., Arnold, T.D., Alitalo, K., Eriksson, L.I., Lendahl, U., 753

It is made available under a CC-BY-NC-ND 4.0 I COVID-19 severity and cerebrovascular burden

- 754 Betsholtz, C., 2020. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 –
- implications for microvascular inflammation and hypercoagulopathy in COVID-19. bioRxiv
- 756 2020.05.11.088500. https://doi.org/10.1101/2020.05.11.088500
- 757 Heijmans, L., Mons, M.R., Joosten, E.A., 2021. A systematic review on descending serotonergic
- projections and modulation of spinal nociception in chronic neuropathic pain and after spinal
- 759 cord stimulation. Molecular pain 17. https://doi.org/10.1177/17448069211043965
- Hensley, M.K., Markantone, D., Prescott, H.C., 2021. Neurologic Manifestations and Complications of
- 761 COVID-19. https://doi.org/10.1146/annurev-med-042320-010427 73.
- 762 https://doi.org/10.1146/ANNUREV-MED-042320-010427
- Hosp, J., DressingA, Blazhenets, G., Bormann, T., Rau, A., Schwabenland, M., Thurow, J., Wagner, D.,
- 764 Waller, C., Niesen, W., Frings, L., Urbach, H., Prinz, M., Weiller, C., Schroeter, N., Meyer, P.,
- 765 2021. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of
- 766 COVID-19. Brain : a journal of neurology 144, 1263–1276.
- 767 https://doi.org/10.1093/BRAIN/AWAB009
- Iadecola, C., Anrather, J., Kamel, H., 2020. Effects of COVID-19 on the Nervous System. Cell 183, 16.
  https://doi.org/10.1016/J.CELL.2020.08.028
- 770 Iba, T., Connors, J.M., Levy, J.H., 2020. The coagulopathy, endotheliopathy, and vasculitis of COVID-
- 771 19. Inflammation Research 2020 69:12 69, 1181–1189. https://doi.org/10.1007/S00011-020772 01401-6
- Jenkinson, M., Bannister, P., Brady, M., Smith, S., 2002. Improved optimization for the robust and
   accurate linear registration and motion correction of brain images. NeuroImage 17, 825–41.
- Jensen, K.E., Thomsen, C., Henriksen, O., 1988. In vivo measurement of intracellular pH in human
  brain during different tensions of carbon dioxide in arterial blood. A 31P-NMR study. Acta
- 777 physiologica Scandinavica 134, 295–8. https://doi.org/10.1111/j.1748-1716.1988.tb08492.x
- 778 Kakarla, V., Kaneko, N., Nour, M., Khatibi, K., Elahi, F., Liebeskind, D.S., Hinman, J.D., 2021.
- Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2:
- 780 https://doi.org/10.1177/0271678X20985666 41, 1179–1192.
- 781 https://doi.org/10.1177/0271678X20985666
- 782 Kaneko, N., Satta, S., Komuro, Y., Muthukrishnan, S.D., Kakarla, V., Guo, L., An, J., Elahi, F., Kornblum,
- 783 H.I., Liebeskind, D.S., Hsiai, T., Hinman, J.D., 2021. Flow-Mediated Susceptibility and Molecular
- 784 Response of Cerebral Endothelia to SARS-CoV-2 Infection. Stroke 260–270.
- 785 https://doi.org/10.1161/STROKEAHA.120.032764

medRxiv preprint doi: https://doi.org/10.1101/2022.02.01.22270235; this version posted February 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 severity and cerebrovascular burden

- 786 Kannurpatti, S.S., Biswal, B.B., 2008. Detection and scaling of task-induced fMRI-BOLD response using
- 787 resting state fluctuations. NeuroImage 40, 1567–74.
- 788 https://doi.org/10.1016/j.neuroimage.2007.09.040
- 789 Keyeux, A., Ochrymowicz-Bemelmans, D., Charlier, A.A., 1995. Induced response to hypercapnia in the
- 790 two-compartment total cerebral blood volume: influence on brain vascular reserve and flow
- 791 efficiency. Journal of cerebral blood flow and metabolism : official journal of the International
- Society of Cerebral Blood Flow and Metabolism 15, 1121–31.
- 793 https://doi.org/10.1038/jcbfm.1995.139
- Khaddaj-Mallat, R., Aldib, N., Bernard, M., Paquette, A.-S., Ferreira, A., Lecordier, S., Saghatelyan, A.,
- 795 Flamand, L., ElAli, A., 2021. SARS-CoV-2 deregulates the vascular and immune functions of brain
- 796 pericytes via Spike protein. Neurobiology of Disease 161, 105561.
- 797 https://doi.org/10.1016/J.NBD.2021.105561
- 798 Kraha, A., Turner, H., Nimon, K., Zientek, L.R., Henson, R.K., 2012. Tools to Support Interpreting
- 799 Multiple Regression in the Face of Multicollinearity. Frontiers in Psychology 3, 44.
- 800 https://doi.org/10.3389/fpsyg.2012.00044
- Krishnan, A., Williams, L.J., McIntosh, A.R., Abdi, H., 2011. Partial Least Squares (PLS) methods for
- 802 neuroimaging: A tutorial and review. NeuroImage 56, 455–475.
- 803 https://doi.org/10.1016/j.neuroimage.2010.07.034
- Lambertsen, C.J., Semple, S.J.G., Smyth, M.G., Gelfand, R., 1961. H<sup>+</sup> and pCO<sub>2</sub> as chemical factors in
- respiratory and cerebral circulatory control. Journal of Applied Physiology 16, 473–484.
- 806 https://doi.org/10.1152/jappl.1961.16.3.473
- Lassen, N.A., 1968. Brain extracellular pH: the main factor controlling cerebral blood flow.
- 808 Scandinavian journal of clinical and laboratory investigation 22, 247–51.
- 809 https://doi.org/10.3109/00365516809167060
- Ledoit, O., Wolf, M., 2004. A well-conditioned estimator for large-dimensional covariance matrices.
- 811 Journal of Multivariate Analysis 88, 365–411. https://doi.org/10.1016/S0047-259X(03)00096-4
- Lersy, F., Anheim, M., Willaume, T., Chammas, A., Brisset, J.-C., Ois Cotton, F., Kremer, S., 2021.
- 813 Cerebral vasculitis of medium-sized vessels as a possible mechanism of brain damage in COVID-
- 814 19 patients. Journal of Neuroradiology 48, 141–146.
- 815 https://doi.org/10.1016/j.neurad.2020.11.004
- Levi, M., Thachil, J., Iba, T., Levy, J.H., 2020. Coagulation abnormalities and thrombosis in patients
- with COVID-19. The Lancet Haematology 7, e438–e440. https://doi.org/10.1016/S2352-
- 818 3026(20)30145-9

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

819 Lindquist, M.A., Geuter, S., Wager, T.D., Caffo, B.S., 2019. Modular preprocessing pipelines can reintroduce artifacts into fMRI data. Human Brain Mapping 40, 2358–2376. 820 821 https://doi.org/10.1002/hbm.24528 Liu, X., Tyler, L.K., Cam-CAN, Rowe, J.B., Tsvetanov, K.A., 2021. Multimodal fusion analysis of 822 823 functional, cerebrovascular and structural neuroimaging in healthy ageing subjects. bioRxiv 824 2021.12.22.473894. https://doi.org/10.1101/2021.12.22.473894 Luan, Y.Y., Yin, C.H., Yao, Y.M., 2021. Update Advances on C-Reactive Protein in COVID-19 and Other 825 Viral Infections. Frontiers in Immunology 12, 3153. 826 827 https://doi.org/10.3389/FIMMU.2021.720363/BIBTEX Mahoney, F.I., Barthel, D.W., 1965. Barthel Index. Maryland State Medical Journal 61–65. 828 Makedonov, I., Black, S.E., Macintosh, B.J., 2013. BOLD fMRI in the white matter as a marker of aging 829 and small vessel disease. PloS one 8, e67652. https://doi.org/10.1371/journal.pone.0067652 830 831 Makedonov, I., Chen, J.J., Masellis, M., MacIntosh, B.J., 2016. Physiological fluctuations in white matter are increased in Alzheimer's disease and correlate with neuroimaging and cognitive 832 biomarkers. Neurobiology of Aging 37, 12–18. 833 834 https://doi.org/10.1016/j.neurobiolaging.2015.09.010 835 Marcic, M., Marcic, L., Marcic, B., Capkun, V., Vukojevic, K., 2021. Cerebral Vasoreactivity Evaluated by 836 Transcranial Color Doppler and Breath-Holding Test in Patients after SARS-CoV-2 Infection. 837 Journal of personalized medicine 11. https://doi.org/10.3390/JPM11050379 Marshall, J.C., Murthy, S., Diaz, J., Adhikari, N.K., Angus, D.C., Arabi, Y.M., Baillie, K., Bauer, M., Berry, 838 S., Blackwood, B., Bonten, M., Bozza, F., Brunkhorst, F., Cheng, A., Clarke, M., Dat, V.Q., Jong, M. 839 840 de, Denholm, J., Derde, L., Dunning, J., Feng, X., Fletcher, T., Foster, N., Fowler, R., Gobat, N., Gomersall, C., Gordon, A., Glueck, T., Harhay, M., Hodgson, C., Horby, P., Kim, Y., Kojan, R., 841 842 Kumar, B., Laffey, J., Malvey, D., Martin-Loeches, I., McArthur, C., McAuley, D., McBride, S., McGuinness, S., Merson, L., Morpeth, S., Needham, D., Netea, M., Oh, M.-D., Phyu, S., Piva, S., 843 Qiu, R., Salisu-Kabara, H., Shi, L., Shimizu, N., Sinclair, J., Tong, S., Turgeon, A., Uyeki, T., 844 845 Veerdonk, F. van de, Webb, S., Williamson, P., Wolf, T., Zhang, J., 2020. A minimal common 846 outcome measure set for COVID-19 clinical research. The Lancet Infectious Diseases 20, e192-847 e197. https://doi.org/10.1016/S1473-3099(20)30483-7 McGonagle, D., Bridgewood, C., Ramanan, A. V, Meaney, J.F.M., Watad, A., 2021. COVID-19 vasculitis 848 and novel vasculitis mimics. The Lancet. Rheumatology 3, e224. https://doi.org/10.1016/S2665-849 850 9913(20)30420-3 Millar, P.R., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Fagan, A.M., Morris, J.C., Balota, D.A., 2020a. 851 852 Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's

medRxiv preprint doi: https://doi.org/10.1101/2022.02.01.22270235; this version posted February 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

disease. Neurobiology of Aging 96, 233–245. 853 https://doi.org/10.1016/J.NEUROBIOLAGING.2020.08.007 854 855 Millar, P.R., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Morris, J.C., Balota, D.A., 2021. Evaluating 856 Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent 857 Variability. Journal of cognitive neuroscience 33, 279–302. 858 https://doi.org/10.1162/JOCN A 01645 859 Millar, P.R., Petersen, S.E., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Morris, J.C., Balota, D.A., 2020b. Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after 860 861 Controlling for Motion and Cardiovascular Inf luences: A Network-Based Approach. Cerebral Cortex 00, 1–16. https://doi.org/10.1093/cercor/bhaa138 862 863 Mitsikostas, D.D., Sanchez Del Rio, M., Waeber, C., 2002. 5-Hydroxytryptamine(1B/1D) and 5hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse 864 865 trigeminal nucleus caudalis. Cephalalgia : an international journal of headache 22, 384–394. https://doi.org/10.1046/J.1468-2982.2002.00382.X 866 Mohkhedkar, M., Venigalla, S.S.K., Janakiraman, V., 2021. Autoantigens That May Explain 867 Postinfection Autoimmune Manifestations in Patients With Coronavirus Disease 2019 Displaying 868 869 Neurological Conditions. The Journal of Infectious Diseases 223, 536–537. 870 https://doi.org/10.1093/INFDIS/JIAA703 871 Nair, V.A., Raut, R. V., Prabhakaran, V., 2017. Investigating the Blood Oxygenation Level-Dependent Functional MRI Response to a Verbal Fluency Task in Early Stroke before and after 872 Hemodynamic Scaling. Frontiers in Neurology 8, 283. https://doi.org/10.3389/fneur.2017.00283 873 874 Nasreddine, Z., Phillips, N., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J., 875 Chertkow, H., 2005. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild 876 cognitive impairment. Journal of the American Geriatrics Society 53, 695–699. https://doi.org/10.1111/J.1532-5415.2005.53221.X 877 Newcombe, V.F.J., Spindler, L.R.B., Das, T., Winzeck, S., Allinson, K., Stamatakis, E.A., Menon, D.K., 878 879 2020. Neuroanatomical substrates of generalized brain dysfunction in COVID-19. Intensive Care 880 Medicine 2020 47:1 47, 116-118. https://doi.org/10.1007/S00134-020-06241-W 881 Nilsson, T., Longmore, J., Shaw, D., Jansen Olesen, I.J., Edvinsson, L., 1999. Contractile 5-HT1B 882 receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. British Journal of Pharmacology 128, 1133–1140. 883 884 https://doi.org/10.1038/SJ.BJP.0702773

COVID-19 severity and cerebrovascular burden

- Nimon, K., Lewis, M., Kane, R., Haynes, R.M., 2008a. An R package to compute commonality 885 coefficients in the multiple regression case: An introduction to the package and a practical 886 887 example. Behavior Research Methods 40, 457–466. https://doi.org/10.3758/BRM.40.2.457 Nimon, K., Lewis, M., Kane, R., Haynes, R.M., 2008b. An R package to compute commonality 888 889 coefficients in the multiple regression case: An introduction to the package and a practical 890 example. Behavior Research Methods 40, 457–466. https://doi.org/10.3758/BRM.40.2.457 891 Passamonti, L., Tsvetanov, K.A., Jones, P.S., Bevan-Jones, W.R., Arnold, R., Borchert, R.J., Mak, E., Su, L., O'Brien, J.T., Rowe, J.B., 2019a. Neuroinflammation and functional connectivity in Alzheimer's 892 893 disease: interactive influences on cognitive performance. The Journal of Neuroscience 39, 2574-18. https://doi.org/10.1523/jneurosci.2574-18.2019 894 Passamonti, L., Tsvetanov, K.A., Jones, P.S., Bevan-Jones, W.R., Arnold, R., Borchert, R.J., Mak, E., Su, 895 L., O'Brien, J.T., Rowe, J.B., 2019b. Neuroinflammation and Functional Connectivity in 896 897 Alzheimer's Disease: Interactive Influences on Cognitive Performance. The Journal of neuroscience : the official journal of the Society for Neuroscience 39. 898 https://doi.org/10.1523/JNEUROSCI.2574-18.2019 899 900 Paterson, R., Brown, R., Benjamin, L., Nortley, R., S, W., T, B., DL, J., G, K., RE, R., L, Z., V, V., A, K., R, G., 901 K, C., E, B., H, T., G, P., G, C., J, M., P, M., B, M., ST, L., PR, M., V, L., S, K., W, Y., SA, T., AJM, F., G, 902 H., TD, M., AD, E., C, C., NWS, D., M, Y., D, A., J, Sreedharan, E, S., JM, S., A, Chandratheva, RJ, P., 903 R, S., A, Checkley, N, L., SF, F., F, C., C, Houlihan, M, T., MP, L., J, Spillane, R, H., A, V., DJ, W., C, Hoskote, Jäger HR, Manji, H., Zandi, M., 2020. The emerging spectrum of COVID-19 neurology: 904 clinical, radiological and laboratory findings. Brain : a journal of neurology 143, 3104–3120. 905 906 https://doi.org/10.1093/BRAIN/AWAA240 PL, E., MA, M., V, B., RP, T., R, M., A, A., AB, N., 2003. The 6-min walk test: a guick measure of 907 908 functional status in elderly adults. Chest 123, 387–398. 909 https://doi.org/10.1378/CHEST.123.2.387 Pruim, R.H.R., Mennes, M., Buitelaar, J.K., Beckmann, C.F., 2015a. Evaluation of ICA-AROMA and 910 911 alternative strategies for motion artifact removal in resting state fMRI. NeuroImage 112, 278– 912 287. https://doi.org/10.1016/j.neuroimage.2015.02.063 Pruim, R.H.R., Mennes, M., van Rooij, D., Llera, A., Buitelaar, J.K., Beckmann, C.F., 2015b. ICA-AROMA: 913 914 A robust ICA-based strategy for removing motion artifacts from fMRI data. NeuroImage 112, 267-277. https://doi.org/10.1016/j.neuroimage.2015.02.064 915
- 916 Raut, R. V., Nair, V.A., Sattin, J.A., Prabhakaran, V., 2016. Hypercaphic evaluation of vascular reactivity
- in healthy aging and acute stroke via functional MRI. NeuroImage: Clinical 12, 173–179.
- 918 https://doi.org/10.1016/j.nicl.2016.06.016

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

919	Rorden, C., Brett, M., 2000. Stereotaxic display of brain lesions. Behavioural neurology 12, 191–200.
920	https://doi.org/10.1155/2000/421719
921	Rostrup, E., Larsson, H.B.W., Toft, P.B., Garde, K., Ring, P.B., Henriksen, O., 1996. Susceptibility
922	Contrast Imaging of CO $_{ m 2}$ -Induced Changes in the Blood Volume of the Human Brain. Acta

923 Radiologica 37, 813–822. https://doi.org/10.3109/02841859609177722

- Rostrup, E., Larsson, H.B.W., Toft, P.B., Garde, K., Thomsen, C., Ring, P., Søndergaard, L., Henriksen,
- 925 O., 1994. Functional MRI of CO2 induced increase in cerebral perfusion. NMR in Biomedicine 7,

926 29–34. https://doi.org/10.1002/nbm.1940070106

- 927 Satterthwaite, T.D., Elliott, M. a, Gerraty, R.T., Ruparel, K., Loughead, J., Calkins, M.E., Eickhoff, S.B.,
- 928 Hakonarson, H., Gur, R.C.R.E., Gur, R.C.R.E., Wolf, D.H., 2013. An improved framework for
- 929 confound regression and filtering for control of motion artifact in the preprocessing of resting-

930 state functional connectivity data. NeuroImage 64, 240–56.

- 931 https://doi.org/10.1016/j.neuroimage.2012.08.052
- 932 Schnaubelt, S., Oppenauer, J., Tihanyi, D., Mueller, M., Maldonado-Gonzalez, E., Zejnilovic, S.,
- Haslacher, H., Perkmann, T., Strassl, R., Anders, S., Stefenelli, T., Zehetmayer, S., Koppensteiner,
- 934 R., Domanovits, H., Schlager, O., 2021. Arterial stiffness in acute COVID-19 and potential

associations with clinical outcome. Journal of internal medicine 290, 437–443.

936 https://doi.org/10.1111/JOIM.13275

- 937 Shi, Y., Thrippleton, M.J., Makin, S.D., Marshall, I., Geerlings, M.I., de Craen, A.J.M., van Buchem, M.A.,
- 938 Wardlaw, J.M., 2016. Cerebral blood flow in small vessel disease: A systematic review and meta-
- analysis. Journal of cerebral blood flow and metabolism : official journal of the International

940 Society of Cerebral Blood Flow and Metabolism 36, 1653–1667.

941 https://doi.org/10.1177/0271678X16662891

- 942 Sibille, E., Su, J., Leman, S., le Guisquet, A.M., Ibarguen-Vargas, Y., Joeyen-Waldorf, J., Glorioso, C.,
- 943 Tseng, G.C., Pezzone, M., Hen, R., Belzung, C., 2007. Lack of serotonin1B receptor expression
- 944 leads to age-related motor dysfunction, early onset of brain molecular aging and reduced

945 longevity. Molecular psychiatry 12, 1042–1056. https://doi.org/10.1038/SJ.MP.4001990

- 946 Tsvetanov, K.A., Gazzina, S., Jones, P.S., Swieten, J., Borroni, B., Sanchez-Valle, R., Moreno, F., Laforce,
- 947 R., Graff, C., Synofzik, M., Galimberti, D., Masellis, M., Tartaglia, M.C., Finger, E., Vandenberghe,
- 948 R., Mendonça, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C., Gerhard, A., Danek, A.,
- 249 Levin, J., Otto, M., Frisoni, G., Ghidoni, R., Sorbi, S., Rohrer, J.D., Rowe, J.B., 2020a. Brain
- 950 functional network integrity sustains cognitive function despite atrophy in presymptomatic
- 951 genetic frontotemporal dementia. Alzheimer's & Dementia alz.12209.
- 952 https://doi.org/10.1002/alz.12209

medRxiv preprint doi: https://doi.org/10.1101/2022.02.01.22270235; this version posted February 2, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

953 Tsvetanov, K.A., Henson, R.N.A., Jones, P.S., Mutsaerts, H., Fuhrmann, D., Tyler, L.K., Rowe, J.B.,

- 954 2020b. The effects of age on resting-state BOLD signal variability is explained by cardiovascular
- and cerebrovascular factors, in: Psychophysiology. Blackwell Publishing Inc.

956 https://doi.org/10.1111/psyp.13714

- 957 Tsvetanov, K.A., Henson, R.N.A., Rowe, J.B., 2020c. Separating vascular and neuronal effects of age on
- 958 fMRI BOLD signals. Philosophical Transactions of the Royal Society B: Biological Sciences.
- 959 https://doi.org/10.1098/rstb.2019.0631
- 960 Tsvetanov, K.A., Henson, R.N.A., Tyler, L.K., Davis, S.W., Shafto, M.A., Taylor, J.R., Williams, N., Rowe,
- 961 J.B., 2015. The effect of ageing on fMRI: Correction for the confounding effects of vascular
- reactivity evaluated by joint fMRI and MEG in 335 adults. Human Brain Mapping 36, 2248–2269.
- 963 https://doi.org/10.1002/hbm.22768
- Tsvetanov, K.A., Henson, R.N.A., Tyler, L.K., Razi, A., Geerligs, L., Ham, T.E., Rowe, J.B., 2016. Extrinsic
- 965 and intrinsic brain network connectivity maintains cognition across the lifespan despite
- accelerated decay of regional brain activation. Journal of Neuroscience 36, 3115–26.
- 967 https://doi.org/10.1523/JNEUROSCI.2733-15.2016
- 968 Tsvetanov, K.A., Ye, Z., Hughes, L., Samu, D., Treder, M.S., Wolpe, N., Tyler, L.K., Rowe, J.B., for
- 969 Cambridge Centre for Ageing and Neuroscience, 2018. Activity and connectivity differences
- 970 underlying inhibitory control across the adult lifespan. The Journal of neuroscience : the official
- journal of the Society for Neuroscience 38, 7887–7900.
- 972 https://doi.org/10.1523/JNEUROSCI.2919-17.2018
- 973 Ulhaq, Z.S., Soraya, G.V., 2020. Interleukin-6 as a potential biomarker of COVID-19 progression.
- 974 Médecine et Maladies Infectieuses 50, 382–383.
- 975 https://doi.org/10.1016/J.MEDMAL.2020.04.002
- 976 Vaishnavi, S.N., Vlassenko, A.G., Rundle, M.M., Snyder, A.Z., Mintun, M.A., Raichle, M.E., 2010.
- 977 Regional aerobic glycolysis in the human brain. Proceedings of the National Academy of Sciences
- 978 of the United States of America 107, 17757–17762.
- 979 https://doi.org/10.1073/PNAS.1010459107/-/DCSUPPLEMENTAL
- 980 Váša, F., Seidlitz, J., Romero-Garcia, R., Whitaker, K.J., Rosenthal, G., Vértes, P.E., Shinn, M.,
- 981 Alexander-Bloch, A., Fonagy, P., Dolan, R.J., Jones, P.B., Goodyer, I.M., Sporns, O., Bullmore, E.T.,
- 982 2018. Adolescent Tuning of Association Cortex in Human Structural Brain Networks. Cerebral
- 983 cortex (New York, N.Y. : 1991) 28, 281–294. https://doi.org/10.1093/CERCOR/BHX249
- 984 Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G.,
- 985 Thompson, H., Walker, P.G.T., Fu, H., Dighe, A., Griffin, J.T., Baguelin, M., Bhatia, S., Boonyasiri,
- 986 A., Cori, A., Cucunubá, Z., FitzJohn, R., Gaythorpe, K., Green, W., Hamlet, A., Hinsley, W., Laydon,

COVID-19 severity and cerebrovascular burden

007	
987	D., Nedjati-Gilani, G., Riley, S., van Elsland, S., Volz, E., Wang, H., Wang, Y., Xi, X., Donnelly, C.A.,
988	Ghani, A.C., Ferguson, N.M., 2020. Estimates of the severity of coronavirus disease 2019: a
989	model-based analysis. The Lancet Infectious Diseases 20, 669–677.
990	https://doi.org/10.1016/S1473-3099(20)30243-7/ATTACHMENT/E32585C1-0F24-46F4-855E-
991	FC2C52BBAFD7/MMC1.PDF
992	Vestergaard, M.B., Jensen, M.L.F., Arngrim, N., Lindberg, U., Larsson, H.B.W., 2020. Higher
993	physiological vulnerability to hypoxic exposure with advancing age in the human brain. Journal
994	of Cerebral Blood Flow & Metabolism 40, 341. https://doi.org/10.1177/0271678X18818291
995	Vlassenko, A.G., Vaishnavi, S.N., Couture, L., Sacco, D., Shannon, B.J., Mach, R.H., Morris, J.C., Raichle,
996	M.E., Mintun, M.A., 2010. Spatial correlation between brain aerobic glycolysis and amyloid- $eta$ (A $eta$
997	) deposition. Proceedings of the National Academy of Sciences of the United States of America
998	107, 17763–17767. https://doi.org/10.1073/PNAS.1010461107
999	Vos de Wael, R., Benkarim, O., Paquola, C., Lariviere, S., Royer, J., Tavakol, S., Xu, T., Hong, S.J., Langs,
1000	G., Valk, S., Misic, B., Milham, M., Margulies, D., Smallwood, J., Bernhardt, B.C., 2020.
1001	BrainSpace: a toolbox for the analysis of macroscale gradients in neuroimaging and
1002	connectomics datasets. Communications Biology 2020 3:1 3, 1–10.
1003	https://doi.org/10.1038/s42003-020-0794-7
1004	Wagerle, L.C., Mishra, O.P., 1988. Mechanism of CO2 response in cerebral arteries of the newborn
1005	pig: Role of phospholipase, cyclooxygenase, and lipoxygenase pathways. Circulation Research
1006	62, 1019–1026. https://doi.org/10.1161/01.RES.62.5.1019
1007	Willie, C.K., Tzeng, YC., Fisher, J.A., Ainslie, P.N., 2014. Integrative regulation of human brain blood
1008	flow. The Journal of physiology 592, 841–59. https://doi.org/10.1113/jphysiol.2013.268953
1009	Wool, G.D., Miller, J.L., 2021. The Impact of COVID-19 Disease on Platelets and Coagulation.
1010	Pathobiology 88, 15–27. https://doi.org/10.1159/000512007
1011	Wu, S., Tyler, L.K., Rowe, J.B., Cam-CAN, Tsvetanov, K.A., 2021. Brain cerebral blood flow explains
1012	behaviour-relevant BOLD responses in fluid ability across the lifespan. In Preparation.
1013	Xu, L., Groth, K.M., Pearlson, G., Schretlen, D.J., Calhoun, V.D., 2009. Source-based morphometry: the
1014	use of independent component analysis to identify gray matter differences with application to
1015	schizophrenia. Human brain mapping 30, 711–24. https://doi.org/10.1002/hbm.20540
1016	Yang, A.C., Vest, R.T., Kern, F., Lee, D.P., Maat, C.A., Losada, P.M., Chen, M.B., Agam, M., Schaum, N.,
1017	Khoury, N., Calcuttawala, K., Pálovics, R., Shin, A., Wang, E.Y., Luo, J., Gate, D., Siegenthaler, J.A.,
1018	McNerney, M.W., Keller, A., Wyss-Coray, T., 2021. A human brain vascular atlas reveals diverse
1019	cell mediators of Alzheimer's disease risk. bioRxiv 2021.04.26.441262.
1020	https://doi.org/10.1101/2021.04.26.441262

COVID-19 severity and cerebrovascular burden

Tsvetanov et. al.

- Zhang, X.J., Qin, J.J., Cheng, X., Shen, L., Zhao, Y.C., Yuan, Y., Lei, F., Chen, M.M., Yang, H., Bai, L., Song, 1021 1022 X., Lin, L., Xia, M., Zhou, F., Zhou, J., She, Z.G., Zhu, L., Ma, X., Xu, Q., Ye, P., Chen, G., Liu, L., Mao, 1023 W., Yan, Y., Xiao, B., Lu, Z., Peng, G., Liu, M., Yang, Jun, Yang, L., Zhang, C., Lu, H., Xia, X., Wang, 1024 D., Liao, X., Wei, X., Zhang, B.H., Zhang, X., Yang, Juan, Zhao, G.N., Zhang, P., Liu, P.P., Loomba, 1025 R., Ji, Y.X., Xia, J., Wang, Y., Cai, J., Guo, J., Li, H., 2020. In-Hospital Use of Statins Is Associated 1026 with a Reduced Risk of Mortality among Individuals with COVID-19. Cell metabolism 32, 176-187.e4. https://doi.org/10.1016/J.CMET.2020.06.015 1027 1028 Zubair, A.S., McAlpine, L.S., Gardin, T., Farhadian, S., Kuruvilla, D.E., Spudich, S., 2020. 1029 Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of
- 1030 Coronavirus Disease 2019: A Review. JAMA Neurology 77, 1018–1027.
- 1031 https://doi.org/10.1001/JAMANEUROL.2020.2065